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 ABSTRACT. A series of imidazo[1,5-a]quinoline derivatives was designed and synthesized as 
central benzodiazepine receptor (CBR) ligands. Most of the compounds showed high CBR affinity 
with Ki values in the submicromolar up to subnanomolar ranges with interesting modulations in their 
structure-affinity relationships. In particular, fluoroderivative 7w (Ki = 0.44 nM) resulted the most 
potent ligand among the imidazo[1,5-a]quinoline derivatives described so far. Overall, these 
observations confirmed the assumption concerning the presence of a large although apparently 
saturable lipophilic pocket in the CBR binding site region interacting with positions 4 and 5 of the 
imidazo[1,5-a]quinoline nucleus. The in vivo biological characterization revealed that compounds 
7a,c,d,l,m,q,r,w showed anxiolytic and antiamnestic activities without the unpleasant myorelaxant 
side-effects of the classical 1,4-BDZ. Furthermore, the effect of 7l,q,r, and 8i in lowering lactate 
dehydrogenase (LDH) release induced by ischemia-like conditions in rat brain slices suggested 
neuroprotective properties for these imidazo[1,5-a]quinoline derivatives. 
 
 INTRODUCTION 
 
The neurotransmitter action of -aminobutyric acid (GABA) at the GABAA chloride channel 
complex modulates the excitability of many central nervous system (CNS) pathways.1 GABAA 
receptors are ligand-gated ion channels (LGICs) belonging to the Cys-loop superfamily, the same of 
nicotinic acetylcholine, glycine, zinc-activated, and 5-HT3 receptors. Cys-loop receptors are 
characterized by the assembling of five subunits, which form a pentameric arrangements around a 
central ion-conducting pore and are the targets of many drugs.1 The function of GABAA receptors is 
regulated, in addition to the agonist binding site, by allosteric sites interacting with a large variety of 
agents.2 Positive modulators of the GABAA receptors, such as the classical 1,4-benzodiazepine 
(BDZ) diazepam (1, Figure 1), are therapeutically employed as sedatives, muscle relaxants, 
anxiolytics and anticonvulsants, whereas negative GABAA modulators (i. e. BDZ inverse agonists) 
show anxiogenic and convulsant effects.3-6 Finally, neutral modulators, such as the imidazo[1,5-
a][1,4]benzodiazepines flumazenil (2), bind to GABAA receptor but have no intrinsic activity at the 
central benzodiazepine receptor (CBR). Thus, flumazenil is recognized to antagonize the activity of 
both positive and negative GABAA modulators acting via the CBR.  
 
Figure 1. Structure of reference compounds. 
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 Since positive modulators show amnesic effects in animal and man,7-10 negative modulators were 
assumed to possess precognitive properties.11-12 However, the use of non-selective CBR inverse 
agonists in the treatment of neurological disorders associated with cognitive impairment was limited 
by their anxiogenic and proconvulsant effects.13  
A large number of subunits (i. e.,  and ) has been cloned and sequenced, 
but most of GABAA receptors are composed of , , and -subunits arranged in a 2:2:1 
stoichiometry.14 In fact, among the multitude of possible combinations deriving from the theoretical 
co-assembling of the subunits, only the receptor subtypes containing a 2 or 315 subunit in 
conjunction with  or 5 appear to bind BDZ ligands with significant affinity. The CBR 
binding domain is assumed to be located at the interface between  and  subunits, which contribute 
with their amino acid residues to the building of the active site.16 Investigations based on molecular 
genetic or pharmacological approaches suggested that1 subunit is involved in the sedative and 
muscle relaxant effects of non-selective BDZ agonists, whereas 2 or 3 can be responsible forthe 
anxiolytic and anticonvulsant effects.17-19 The recognition of pharmacological and physiological 
roles of α subunits in GABAA receptor subtype functions has stimulated new interest in this receptor 
system as the target for the development of drugs showing minor side-effects with respect to the 
classical benzodiazepines (e. g. non-sedating anxiolytics) or with indications that are different from 
those of classical benzodiazepines (e. g. analgesics, cognition-enhancing drugs).20-27 A number of 
compounds has been developed that show GABAA receptor subtype selectivity, either by affinity or 
efficacy, or both.20 In fact, subtype-selective GABAA receptor ligands can be obtained either by 
selective binding (i. e. by forming a receptor-ligand complex with a particular receptor subtype) or 
by selective efficacy (i. e. by eliciting a biological response after binding to the receptor). These two 
properties are both important in defining the potency profile.20 
Very interestingly, a full range of intrinsic efficacy was observed in the series of imidazo[1,5-
a][1,4]benzodiazepine derivatives 3 that was modulated in a rather subtle manner by the substitution 
pattern.28,29 A similar behavior was observed when the seven-membered ring of the benzodiazepine 
system was contracted as in the series of imidazo[1,5-a]quinoxaline derivatives 4, which have been 
 developed in Upjohn laboratories in the 90’s.30-35 The large body of work performed by the Upjohn 
researchers led to propose the existence of a second low affinity-binding site on GABAA receptors, 
the occupancy of which (at high drug concentrations) may reverse the positive allosteric action on 
CBR and potentially minimize dependence and abuse liability.36 
Among the large number of imidazo[1,5-a]quinoxaline derivatives developed, compound 4a (see 
Figure 1) was shown to induce a negative allosteric modulation via this second low affinity binding 
site.36   Based on the huge amount of structure-activity relationship (SAR) data on imidazo[1,5-
a]quinoxaline derivatives 4, the structure of 4a was easily translated into the imidazo[1,5-
a]quinoline one of 5 (see Figure 1), which was considered as a drug candidate for the treatment of 
anxiety, but its development was discontinued for safety reason (i. e. centrally mediated respiratory 
depression as the toxicity leading to the lethality).37 The identification of 5 as candidate for 
development studies was apparently performed among a limited set of imidazo[1,5-a]quinoline 
derivatives so that the available SAR data on this class of CBR ligands is limited. In general, the 
analysis of the available SAR data suggested that bulky substituents are tolerated by CBR binding 
site when they are located in the ligand region corresponding to the positions 4 and 5 of the 
imidazo[1,5-a]quinoline nucleus in analogy with the results obtained with 5-HT3 receptor ligands 
based on quinoline structure 6.38,39 Similarly, these bulky substituents appeared to play a role in 
modulating the intrinsic efficacy.39 These observations, taken together with the structural analogies 
existing between GABAA and 5-HT3 receptors, led us to apply the approach used in studying 5-HT3 
receptors to the characterization of CBR binding features by means of the design, synthesis, and 
pharmacological characterization of imidazo[1,5-a]quinoline derivatives 7, 8, and 9, in comparison 
with reference imidazo[1,5-a]quinoxalines 10 (Figure 2). 
 
  
 
 
Figure 2. Design of imidazo[1,5-a]quinoline 7-9 starting from piperazinylquinoline 5-HT3 receptor 
ligands  6. 
 
RESULTS AND DISCUSSION  
 
Chemistry. The preparation of target imidazo[1,5-a]quinoline derivatives was performed by 
imidazo-annulation of suitable 2-chloroquinoline derivatives 11-24 with ethyl isocyanoacetate or 
tert-butyl isocyanoacetate in the presence of potassium tert-butoxide providing 7a-i,k-m,o-y 
(Scheme 1) in the yields reported in Table 1. The structure of 7p,s,t was confirmed by 
crystallographic studies (see Supporting Information). 
 
Scheme 1. Imidazo-annulation of 2-chloroquinoline derivatives 11-24 to target imidazo[1,5-
a]quinoline derivatives 7a-i,k-m,o-y. 
 
 
Reagents: (i) CNCH2COOC2H5 or CNCH2COOC(CH3)3, tert-BuOK, DMF. Substituents: see Table 
1. 
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 Table 1. Preparation of target compounds 7a-i,k-m,o-y. 
target target X Y Z R starting source starting Yield 
AB177 7a OC2H5 N(CH3)2 H H 11 see SI AB176 35% 
AB178 7b OC(CH3)3 N(CH3)2 H H 11 see SI AB176 59% 
AB180 7c OC2H5 N(CH3)n-C4H9 H H 12 see SI AB179 10% 
AB181 7d OC(CH3)3 N(CH3)n-C4H9 H H 12 see SI AB179 17% 
AB144A 7e OC2H5 N(n-C3H7)2 H H 13 see ref 38 AB143a 72% 
AB147 7f OC(CH3)3 N(n-C3H7)2 H H 13 see ref 38 AB143a 48% 
AB174 7g OC2H5 N(CH3)CH2C6H5 H H 14 see ref 38 AB173 56% 
AB175 7h OC(CH3)3 N(CH3)CH2C6H5 H H 14 see ref 38 AB173 36% 
AB146 7i OC2H5 N(C2H4)2NCH3 H H 15 see ref 40 AB143b 25% 
AB166 7k OC2H5 OC(CH3)3 H CH3 16 Scheme 2 AB165 94% 
AB144P 7l OC2H5 N(n-C3H7)2 H CH3 17 see ref 38 VC343 60% 
AB145 7m OC(CH3)3 N(n-C3H7)2 H CH3 17 see ref 38 VC343 46% 
AB169 7o OC2H5 N(CH3)CH2C6H5 H CH3 18 see ref 38 VC347 26% 
AB172 7p OC(CH3)3 N(CH3)CH2C6H5 H CH3 18 see ref 38 VC347 46% 
AB151 7q OC2H5 N(n-C3H7)2 H C2H5 19 see ref 38 VC588 27% 
AB152 7r OC(CH3)3 N(n-C3H7)2 H C2H5 19 see ref 38 VC588 15% 
AB160 7s OC2H5 N(C2H5)2 H n-C3H7 20 see ref 38 VC668 21% 
AB161 7t OC(CH3)3 N(C2H5)2 H n-C3H7 20 see ref 38 VC668 55% 
AB157 7u OC2H5 N(n-C3H7)2 H n-C3H7 21 see ref 38 VC592 5% 
AB158 7v OC(CH3)3 N(n-C3H7)2 H n-C3H7 21 see ref 38 VC592 4% 
AB188 7w OC2H5 N(n-C3H7)2 F H 22 Scheme 3 AB187 21% 
AB 186 7x OC2H5 N(CH3)CH2C6H5 F H 23 Scheme 3 AB185 15% 
AB197 7y OC2H5 N(CH3)CH2C6H5 Br H 24 Scheme 3 AB196 62% 
 
The starting 2-chloroquinoline derivatives were known compounds (see Table 1) or were prepared 
by standard methodology.38,40  On the other hand, target propargylamide derivative 7n was 
synthesized from tert-butyl ester 7k via acid 7j (Scheme 2). 
 
  
 Scheme 2. Synthesis of target derivatives 7j,k,n.  
 
 
Reagents: (i) tert-BuOK, THF; (ii) CNCH2COOC2H5, tert-BuOK, DMF; (iii) HCOOH; (iv) SOCl2; 
(v) N-methylpropargylamine, CH2Cl2.  
Acyl chloride 2538 was reacted with potassium tert-butoxide in dry THF to obtain ester 16, which 
was used in the above-described imidazo-annulation with ethyl isocyanoacetate affording diester 7k. 
The cleavage of the tert-butyl ester moiety of the latter with formic acid gave the expected 
carboxylic acid 7j, which was in turn transformed via acyl chloride into the expected 
propargylamide 7n.  
The target imidazo[1,5-a]quinoline derivatives bearing substituents in position 7 of the tricyclic 
nucleus was carried out as outlined in Scheme 3.  
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 Scheme 3. Synthesis of the target imidazo[1,5-a]quinoline derivatives bearing substituents in 
position 7. 
 
 
Reagents: (i) POCl3; (ii) SOCl2; (iii) amine, CH2Cl2, TEA; (iv) CNCH2COOC2H5, tert-BuOK, 
DMF; (v) trimethylsilylacetylene, Pd(PPh3)2(AcO)2, TEA; (vi) Bu4NF, THF. Substituents: Z = F in 
22, 23, 26a, and 27a; Z = Br in 24, 26b, and 27b; Y = N(n-C3H7)2 in 7w and 22; Y = 
N(CH3)CH2C6H5 in 7x,y, 23 and 24. 
 
The appropriately substituted quinolinone derivatives 26a,b41 were converted in the corresponding 
2-chloroquinoline derivatives 27a,b by reaction with phosphorous oxychloride. The amidation of the 
carboxyl group of 27a,b afforded the expected amides 22-24, which were used in the above-
described imidazo-annulation with ethyl isocyanoacetate or tert-butyl isocyanoacetate to obtain 
target compounds 7w,x,y. Bromoderivative 7y was then used in Sonogashira coupling reaction with 
trimethylsilylacetylene to afford 7aa, which was promptly desilylated with into 7z. 
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 Most of the target imidazo[1,5-a]quinoline derivatives bearing the phenyl substituents in position 5 
of the tricyclic nucleus was accomplished as sketched in Scheme 4, while the preparation of 
compound 8i is described in Scheme 5. 
 
Scheme 4. Synthesis of the target imidazo[1,5-a]quinoline derivatives bearing the phenyl 
substituents in position 5. 
 
 
Reagents: (i) CNCH2COOC2H5 or CNCH2COOC(CH3)3, tert-BuOK, DMF; (ii) HCOOH; (iii) 
2,3,5,6-tetrafluorophenol, EDC, Na2CO3, H2O, CH3CN; (iv) HN(CH3)2 for 8c (or HN(CH3)CH2C6H5 
for 8d,f), THF. Substituents: R = H in 8a-d, 28, and 32; R = CH3 in 8e,f, 29, and 33; R = COOC2H5 
in 8g and 30; R = CH2COOC2H5 in 8h and 31; X = OC2H5 in 8a,g,h; X = OC(CH3)3 in 8b,e; X = 
N(CH3)2 in 8c; X = N(CH3)CH2C6H5 in 8d,f. 
 
Imidazo-annulation of suitable 2-chloro-4-phenylquinoline derivatives 28-3142 with ethyl 
isocyanoacetate or tert-butyl isocyanoacetate in the presence of potassium tert-butoxide gave target 
derivatives 8a,b,e,g,h. The cleavage of the tert-butyl ester moiety of esters 8b,e with formic acid 
gave carboxylic acid derivatives 32 and 33, which were converted via 2,3,5,6-tetrafluorophenyl 
esters into the desired amides 8c,d,f.  
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 Scheme 5. Synthesis of the imidazo[1,5-a]quinoline derivative 8i. 
 
 
Reagents: (i) LiAlH4, THF; (ii) TBDMSCl, imidazole, CH2Cl2; (iii) CNCH2COOC2H5, tert-BuOK, 
DMF; (iv) Bu4NF, THF. 
 
Lithium aluminium hydride reduction of ester 30 gave hydroxymethylquinoline derivative 34, which 
was first protected by reaction with tert-butyldimethylsilyl chloride (TBDMSCl) and then submitted 
to the conditions of the imidazo-annulation with ethyl isocyanoacetate or tert-butyl isocyanoacetate 
to afford imidazo[1,5-a]quinoline 36, which was promptly desilylated into target 8i. 
Finally, the imidazo-annulation was applied also to chloroderivative 3743 to obtain tetracyclic target 
compound 9, and to quinoxalinone derivatives 38 and 39.31 However, these latter intermediates 
required a more complex reaction pathway consisting in a first activation step with diethyl 
chlorophosphate followed by a second step of annulation with ethyl isocyanoacetate or tert-butyl 
isocyanoacetate in the presence of potassium tert-butoxide to obtain reference imidazo[1,5-
a]quinoxaline 10a-d (Scheme 6).31 The structure of 10a-c was confirmed by crystallographic studies 
(see Supporting Information). 
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 Scheme 6. Synthesis of target compounds 9 and 10a-d. 
 
 
Reagents: (i) CNCH2COOC2H5, tert-BuOK, DMF; (ii) tert-BuOK, (C2H5O)2POCl, THF; (iii) 
CNCH2COOC2H5 or CNCH2COOC(CH3)3, tert-BuOK, THF. Substituents: X = H in 10a,b and 38; 
X = F in 10c,d and 39; R = C2H5 in 10a,c; R = C(CH3)3 in 10b,d. 
 
In vitro binding. The affinity of the imidazo[1,5-a]quinoline derivatives 7a-aa, 8a-g, 9 and 10a-c 
for CBR in bovine cortical membranes was measured by means of competition experiments against 
the radiolabeled antagonist [3H]flumazenil. The results of the binding studies are expressed as Ki 
values in Tables 2 and 3. The in vitro efficacy of the target compounds was tentatively estimated by 
measuring the GABA ratio (GR, expressed as a ratio of Ki without GABA/Ki with GABA), which is 
considered reasonably predictive of the pharmacological profile of a CBR ligand.44-47 Usually, this 
value approximates 2 for full agonists and 1 for antagonists, while partial agonists show intermediate 
values between 1 and 2; finally, GABA ratio values below 1 are typical for inverse agonists.  
Most of the compounds was found to inhibit specific binding of radiolabeled flumazenil at the 
bovine CBR with Ki values in the submicromolar up to subnanomolar ranges with the full range of 
the intrinsic efficacy as predicted by GABA ratio values (0.52-1.6). 
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 Table 2. Inhibition of [3H]flumazenil specific binding to CBR in cortical membranes and GABA 
ratio values of compounds 7a-aa. 
 
 Compd X Y Z R Ki ± SEMa  
(nM) 
GABA 
ratiob 
AB177 7a OC2H5 N(CH3)2 H H 8.2 ± 2.3 1.3 
AB178 7b OC(CH3)3 N(CH3)2 H H 11 ± 1.9 1.6 
AB180 7c OC2H5 N(CH3)n-C4H9 H H 1.9 ± 0.7 0.76 
AB181 7d OC(CH3)3 N(CH3)n-C4H9 H H 1.8 ± 0.5 0.62 
AB144A 7e OC2H5 N(n-C3H7)2 H H 0.91 ± 0.01 1.0 
AB147 7f OC(CH3)3 N(n-C3H7)2 H H 1.2 ± 0.5 1.1 
AB174 7g OC2H5 N(CH3)CH2C6H5 H H 20 ± 2.9 0.52 
AB175 7h OC(CH3)3 N(CH3)CH2C6H5 H H 14 ± 0.35 0.98 
AB146 7i OC2H5 N(C2H4)2NCH3 H H 55 ± 4.5 1.0 
AB168  7j OC2H5 OH H CH3 105 ± 26 1.2 
AB166 7k OC2H5 OC(CH3)3 H CH3 1.0 ± 0.37 1.4 
AB144P 7l OC2H5 N(n-C3H7)2 H CH3 1.5 ± 0.08 1.3 
AB145 7m OC(CH3)3 N(n-C3H7)2 H CH3 1.0 ± 0.03 1.1 
AB171 7n OC2H5 N(CH3)CH2CCH H CH3 1.2 ± 0.02 1.0 
AB169 7o OC2H5 N(CH3)CH2C6H5 H CH3 6.5 ± 0.4 1.1 
AB172 7p OC(CH3)3 N(CH3)CH2C6H5 H CH3 2.6 ± 0.1 1.0 
AB151 7q OC2H5 N(n-C3H7)2 H C2H5 2.5 ± 0.3 1.5 
AB152 7r OC(CH3)3 N(n-C3H7)2 H C2H5 5.6 ± 0.4 1.4 
AB160 7s OC2H5 N(C2H5)2 H n-C3H7 169 ± 14 0.9 
AB161 7t OC(CH3)3 N(C2H5)2 H n-C3H7 2870 ± 250 1.1 
AB157 7u OC2H5 N(n-C3H7)2 H n-C3H7 34 ± 4.5 1.1 
AB158 7v OC(CH3)3 N(n-C3H7)2 H n-C3H7 1437 ± 120 1.0 
AB188 7w OC2H5 N(n-C3H7)2 F H 0.44 ± 0.2 0.8 
AB 186 7x OC2H5 N(CH3)CH2C6H5 F H 5.7 ± 2.6 0.8 
AB197 7y OC2H5 N(CH3)CH2C6H5 Br H 24 ± 1.7
c
 0.90
c
 
AB199 7z OC2H5 N(CH3)CH2C6H5 CCH H 161 ± 24
c
 0.95
c
 
AB198 7aa OC2H5 N(CH3)CH2C6H5 CCSi(CH3)3 H 510 ± 48
c
 0.99
c
 
 flunitrazepam     5.2 ± 0.2 1.68 
 flumazenil     1.9 ± 0.09 1.03 
  
aKi values are means ± SEM of three independent determinations in bovine cortical membranes. 
bGABA ratio = (Ki without GABA/Ki with 50 M GABA). cThe values were obtained in rat cortical 
membranes.  
  
 Table 3. Inhibition of [3H]flumazenil specific binding to CBR in cortical membranes and GABA 
ratio values of compounds 8a-i, 9 and 10a-d. 
 
 
    bovine  human  
 Compd X R Ki ± SEMa  
(nM) 
GABA 
ratiob 
Ki ± SEMa 
(nM) 
GABA 
ratiob 
AB123 
(EP238,162) 
8a OC2H5 H 42 ± 9.6 0.9   
AB189 8b OC(CH3)3 H 55 ± 32 0.8   
AB192 
(VC885) 
8c N(CH3)2 H 3515 ± 360 1.44   
AB191 
(VC886) 
8d N(CH3)CH2C6H5 H 449 ± 10 0.92   
AB203 8e OC(CH3)3 CH3 10 ± 2.8 1.0   
AB206 8f N(CH3)CH2C6H5 CH3 > 1000
c
    
AB128 8g OC2H5 COOC2H5 2193 ± 633 0.66   
AB129 8h OC2H5 CH2COOC2H5 3.8 ± 2.1 0.72   
AB134 8i OC2H5 CH2OH 1.8 ± 0.1 1.18 2.0 ± 0.2  
AB124 9   18 ± 3.5 1.3   
AB84 10a H C2H5 25 ± 9.6 0.90 33 ± 4.2  
QNX13h 10b
d
 H C(CH3)3 7.3 ± 1.5 0.98 7.7 ± 1.3 1.04 
AB85 10c F C2H5 2.2 ± 0.42 0.75 2.7 ± 0.3 0.95 
AB86 10d F C(CH3)3 1.0 ± 0.46 1.0 2.0 ± 0.3 1.0 
 flunitrazepam   5.2 ± 0.2 1.68 6.4 ± 0.5 1.61 
 flumazenil   1.9 ± 0.09 1.03 2.0 ± 0.08 1.02 
 
aKi values are means ± SEM of three independent determinations. 
bGABA ratio = (Ki without 
GABA/Ki with 50 M GABA). c19% displacement at 1000 nM. dSee ref 31. 
 
The analysis of the structure-activity relationships confirmed the importance of the substituents in 
positions 4 and 5 of the imidazo[1,5-a]quinoline scaffold in modulating both CBR  affinity and 
intrinsic efficacy (Figure 3). The most potent CBR ligands were obtained in the series of 
imidazo[1,5-a]quinoline derivatives bearing a N,N-dipropylaminocarbonyl group at position 5 of the 
tricyclic nucleus. However, also other lipophilic substituents are tolerated in the binding site region 
interacting with position 5 of the imidazo[1,5-a]quinoline namely N,N-dimethylaminocarbonyl, N-
methybutylaminocarbonyl, N-methypropargylaminocarbonyl, N-methybenzylaminocarbonyl, tert-
butoxycarbonyl, and phenyl  groups (Figure 3).  
  
   
Figure 3. SAR in imidazo[1,5-a]quinoline derivatives 7a-i and 7j-p. Effects of the lipophilic 
substituents in position 5.  
 
However, the tolerance to large substituents in position 5 appeared to be conditioned by the presence 
of additional steric bulk in position 4 of the tricyclic scaffold (Figure 4).  
 
Figure 4. SAR in imidazo[1,5-a]quinoline derivatives 7e,f,l,m,q,r,u,v and 8a,b,e,g,h,i. Effects of 
the alkyl substituents in position 4.  
 
In fact, in the dipropylamido sub-series (Figure 4), the increase of the alkyl side chain length led to a 
stepwise decrease in CBR affinity with a rapid acceleration in propyl derivatives 7u,v. This result 
can be rationalized in terms of interactions between the ester group and the alkyl moiety in position 
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 4, but also with the assumption that the lipophilic pocket can be saturated as previously observed in 
5-HT3 receptors.
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On the other hand, in the imidazo[1,5-a]quinoline sub-series bearing a phenyl group in position 5 
(Figure 4), the effects of the substituents in position 4 were highly variable and appeared to depend 
on the stereoelectronic features of the substituent itself. 
In general, small substituents such as H, CH3 and CH2OH are tolerated better than the bulkier 
carbethoxy group of compound 8g, but the spacing of the ester group by a methylene bridge as in 8h 
restored nanomolar CBR affinity suggesting the involvement of specific interactions. 
As already observed in related CBR ligands, the presence of small atoms such as H or F in position 7 
is required for nanomolar CBR affinity, whereas the presence of the bulkier bromine atom produces 
a significant drop in CBR affinity that became almost two orders of magnitude when alkyne 
substituents are present in this position as in compounds 7z-aa (Figure 5).  
 
Figure 5. SAR in imidazo[1,5-a]quinolines 7e,g,w,x,y,z,aa and reference imidazo[1,5-
a]quinoxalines 10a-d. Effects of the substituents in position 7. 
 
It is noteworthy that the beneficial effect of the fluorine substituent was less evident in imidazo[1,5-
a]quinoline derivatives 7w,x than in imidazo[1,5-a]quinoxaline derivatives 10c,d. However, by 
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 virtue of its subnanomolar CBR affinity (Ki = 0.44 nM) fluoroderivative 7w resulted more potent 
than the corresponding imidazo[1,5-a]quinoxaline derivative 10c and is the most potent ligand 
among the imidazo[1,5-a]quinoline derivatives described so far. 
Finally, the replacement of ester groups in position 3 of imidazo[1,5-a]quinoline derivatives 8a,b,e 
with the amide ones of 8c,d,f (Figure 6) was deleterious from the point of view of the interaction 
with CBR binding site producing low affinity ligands. 
 
 
Figure 6. SAR in imidazo[1,5-a]quinolines 8a-f. Effects of the substituents in position 3. 
 
In vitro efficacy in 36Cl- uptake assay in rat cerebrocortical synaptoneurosomes. The comparison 
of GABA ratio values showed a rather complex pattern in the structure-activity relationships of 
imidazo[1,5-a]quinoline derivatives 7a-aa, 8a-g, 9 and 10a-c.  In general, the agonist-like properties 
appeared to be linked to the presence of relatively small substituents (i. e. 7a,b), whereas the 
presence of large lipophilic substituents appeared to be associated to antagonist-like features. 
However, in the same sub-series were present ligands showing apparently different intrinsic efficacy 
without evidencing a clear trend. This could be due both to the complexity of the interaction and to 
the possible experimental errors. 
Thus, the predictive capability of GABA ratio values was evaluated in the limited set of reference 
imidazo[1,5-a]quinoxaline derivatives 10b-d by means of a more direct measure of in vitro efficacy 
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 consisting in 36Cl- uptake assay in rat cerebrocortical synaptoneurosomes.48,49 The synaptic chloride 
conductance effected by GABA activating the GABAA receptor complex is modulated by ligands 
acting at the CBR. In particular, agonists increase the current, antagonists are ineffective, and 
inverse agonists decrease ion flow. The results shown in Figure 7 suggested that reference 10b 
behaved as a CBR antagonist in agreement with its GABA ratio values (0.98-1.04) and with the data 
described in the literature.31  
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Figure 7. 36Cl- uptake measured in rat cerebrocortical synaptoneurosomes for compounds 10b 
(QNX13h, magenta), 10c (AB85, blue), 10d (AB86, cyan), flunitrazepam (empty circles), 
flumazenil (empty diamonds), and ethyl -carboline (empty squares).  
 
Compound 10d (GABA ratio = 1.0) showed a very slight increase of 36Cl- influx, behaving as a 
partial agonist characterized by a very low intrinsic efficacy. On the other hand, an even slight 
decrease in the ion flow was observed with compound 10c (GABA ratio in bovine CBR = 0.75, in 
human CBR = 0.95), which could be therefore classified either as a partial inverse agonist showing a 
very low intrinsic efficacy or as an antagonist. No massive 36Cl- influx was promoted by these 
reference compounds in agreement with their antagonist-like or partial inverse agonist properties as 
predicted by GABA ratio values. On the whole, these apparent discrepancies stressed the importance 
of a suitable biological characterization of the newly synthesized CBR ligands in order to appreciate 
 their pharmacological profile. 
 
In vitro efficacy in excytotoxic-mediate injury. The disruptions in GABA signaling is involved in 
many acute and chronic neurodegenerative disorders such as temporal lobe epilepsy, Parkinson's 
disease (PD), Huntington's disease (HD) and brain ischemia. GABAergic system, in fact, is 
indispensable for maintaining the balance between excitation and inhibition required for normal 
neuronal function. An imbalance between these systems contribute to excitotoxicity and neuronal  
cell death. Consequently, modulation of the GABAergic system can successfully reverse 
excitotoxic-induced injury in disease models, suggesting that therapeutic strategies targeting the 
GABAergic system could be effective in treating neurodegenerative disorders.50-52 Positive 
modulators of the GABAA receptors, such as diazepam and the partial agonist imidazo[1,5-
a]quinoline derivative 5 have been proven to show neuroprotective properties in different models of 
excytotoxic-mediate injury.53-57 Therefore, imidazo[1,5-a]quinoline derivatives 7l (AB144P), 7q 
(AB151), 7r (AB152), and 8i (AB134) were selected on the basis of their Ki and GABA ratio values 
(i. e.  nanomolar CBR affinity and partial agonist profile) and tested for their potential 
neuroproprotective activity. Rat cortical brain slices were subjected to excitotoxic-mediated damage 
(i. e. oxygen-glucose deprivation and reoxygenation, OGD/R) and neuronal injury/neuroprotection 
was assessed by measuring the release of lactate dehydrogenase (LDH). All drug molecules were 
added during reperfusion and their effects were compared to those exerted by diazepam. The results 
demonstrate that diazepam exerted neuroprotective effects according to a "U-shaped", hormetic-like, 
concentration-response curve, with an efficacy window of 0.5-10 µM (Figure 8). In this range, the 
maximum recovery in LDH release was 55.9% which was observed at both 1 and 5 µM 
concentrations (Table 4). 
  
Figure 8. Effects of 7l (AB144P), 7q (AB151), 7r (AB152), 8i (AB134), and diazepam on oxygen–
glucose deprivation and reoxygenation (OGD/R)-induced release of LDH of rat brain cortical slices. 
Slices were incubated in artificial cerebrospinal fluid (ACSF) for 120 min (control conditions, 
CTRL) or subjected for 30 min to oxygen/glucose deprivation followed by 90 min incubation in 
normally oxygenated ACSF (reperfusion). Increasing concentrations of the compounds (0.1–100 
µM) were added to ACSF during the 90 min reperfusion phase. Data are means ± S.E.M. of at least 
4 different experiments. °°°P < 0.01 vs CTRL; *P < 0.05, **P < 0.01, ***P < 0.001 vs OGD/R 
(ANOVA followed by Dunnet post test). 
 
The hormetic effect of diazepam was already observed54 and might be explained by considering that 
elevated diazepam levels at the synaptic cleft might cause an excessive activation of GABAA 
receptors, which aggravates the overload of Cl− and provokes GABAA desensitisation, thus causing 
depolarization and damage to neurons.58,59 In the same way, imidazo[1,5-a]quinoline derivatives 7l 
(AB144P), 7q (AB151), 7r (AB152), and 8i (AB134) showed neuroprotective properties. All the 
compounds, in fact, reduced OGD/R-induced LDH release in an hormetic-like fashion although with 
different efficacy windows. In particular, 8i (AB134) and 7r (AB152) were the most interesting 
 compounds (Figure 8) since they exerted their effects in a wider concentration range than diazepam 
(i. e. 1-25 µM 8i (AB134) or 1-50 µM 7r (AB152)) but the maximum recovery in LDH release was 
lower (39.5% and 44.4%, respectively, at 5 µM, see Table 4). Also 7l (AB144P), 7q (AB151) 
reverted the release of the endocellular enzyme caused by the ischemia-like conditions but the 
maximum effect was observed at 50 µM concentration and the recovery was 44%. Taken together, 
these results suggests that 7l (AB144P), 7q (AB151), 7r (AB152), and 8i (AB134) could behave as 
partial agonists at GABAA receptors in the present experimental model since they exhibited lower 
efficacy than the positive GABAA modulator diazepam. 
 
Table 4. Effects of 7l (AB144P), 7q (AB151), 7r (AB152), 8i (AB134), and diazepam on oxygen–
glucose deprivation and reoxygenation (OGD/R)-induced release of LDH of rat brain cortical slices.  
 Compd Efficacy Windowa 
(µM) 
ECb 
(µM) 
Recoveryc  
(% ) 
AB144P 7l 5-50 50 44.0 ± 8.5* 
AB151 7q 5-100 50 44.3 ± 4.8*** 
AB152 7r 1-50 5 44.4 ± 2.4*** 
AB134 8i 1-25 5 39.5 ± 5.6*** 
diazepam 1 0.5-10 1 
5 
55.9 ± 7.1*** 
55.9 ± 5.9*** 
Rat cortical brain slices were subjected to oxygen-glucose deprivation and reoxygenation and 
neuronal injury/neuroprotection was assessed by measuring the release of lactate dehydrogenase 
(LDH). All drugs were added during reperfusion. aThe efficacy windows represent the range of 
concentrations at which a significant reduction of OGD and reperfusion-induced LDH release was 
observed. bEC (Effective Concentration) is the µM concentration at which the highest reduction was 
observed. cThe Recovery value represents the % of reversion exerted at EC concentration; 100% was 
taken as the return to basal values (CTRL). Recovery data are reported as mean ± esm and the 
comparison between values was performed by using ANOVA followed by Dunnet post hoc test.*P < 
0.05, ***P < 0.001 vs OGD/R. 
 
 In vivo efficacy. Newly synthesized compounds 7a,c,d,l,m,p,q,r,w were evaluated in mice as 
modulators of central nervous system functionalities after per os administration. In particular, four 
pharmacological actions were taken into consideration. The light-dark box test was used to ascertain 
the potential anxiolytic effect, while the rota-rod test measured the myorelaxant effect, the hole-
board test was performed to assess the effects on mouse spontaneous motility and explorative 
activity, and passive avoidance test was finally used to evaluate the mouse learning and memory 
impairment.  
The anxiolytic effect of the molecules is shown in Figure 9. The light-dark box test is based on the 
innate aversion of rodents to the brightly illuminated and open areas and on the spontaneous novelty-
induced exploratory behavior allowing the evaluation of potential anxiolytic compounds. All 
compounds, with the exception of 7p, increased the time spent in the light box after dosing at 10 mg 
kg-1. Compounds 7d (167.2 ± 6.5 s), 7r (172.5 ± 7.2 s) and 7w (181.4 ± 8.3 s) were the most 
effective showing a comparable effect with diazepam (1 mg kg-1 subcutaneously) (Figure 9). 
Compound 7d presented a dose-dependent anxiolytic effect since it was significant starting from 3 
mg kg-1 (144.8 ± 6.3 s; data not shown). A similar potency was showed by compound 7l, which was 
active starting from 3 mg kg-1 (153.4 ± 6.1 s; data not shown) peaking at 10 mg kg-1 (Figure 9). 
Compound 7m was the most potent since it was effective at 1 mg kg-1 (Figure 9), whereas 7p was 
ineffective when administered at 1 and 10 mg kg-1 (Figure 9), but increasing the dose to 30 mg kg-1 
the time was enhanced up to 139.2 ± 5.1 s (data not shown). 
 
 Figure 9. Light-dark box test. Anxiolytic activity. The new compounds were administered per os, 
diazepam (1 mg kg-1) was administered subcutaneously. All treatments were performed 30 min 
before the test. Each value represents the mean ± SEM of at least 10 mice. **P < 0.01 in comparison 
to vehicle-treated mice. 
 
In order to validate the behavioral measurements, possible neurological or muscular side effects of 
the tested compounds were excluded by the hole-board and the rota-rod tests. All the compounds (10 
mg kg-1) did not alter the neurological and muscular abilities of mice as evaluated by the hole-board 
test 30 min after treatment. The number of movements (motor activity) and number of inspections 
(exploratory activity) were comparable to vehicle-treated animals (Figure 10).  
 
Figure 10. Hole-board test. Effects on neurological and muscular abilities. All compounds were 
administered per os 30 min before the test. Each value represents the mean ± SEM of at least 10 
mice.  
 
Similarly, no negative effects on motor coordination emerged in the rota-rod test (Figure 11). 
Treated animals showed a progressive ability to maintain the balance on a rotating rod.  
  
Figure 11. Rota-rod test. Effects on motor coordination. All compounds were administered per os 
30 min before the test. Each value represents the mean ± SEM of at least 10 mice. 
 
The nootropic effects were assessed in the passive avoidance test measuring the prevention of 
scopolamine-induced amnesia. The muscarinic antagonist drastically reduced the time spent in the 
light box of the apparatus during the retention session (44.8 ± 8.1 s vs 101.4 ± 7.0 s of vehicle-
treated animals; 2nd experimental day) highlighting a lack of memory of the punishment received in 
the dark box (Figure 12). Compounds 7c, 7d, 7l, 7m, 7p, 7q, 7r, and 7w (10 mg kg-1) were able to 
significantly prevent scopolamine-induced amnesia (Figure 12). Compound 7w was the most 
effective (99.6 ± 9.2 s), both 7r and 7w were effective also at 1 mg kg-1. Compound 7d was effective 
starting from 3 mg kg-1 (73.5 ± 8.8 s; data not shown). Ten mg kg-1 compound 7p was not effective 
in the passive avoidance test (Figure 12). However the dose of 30 mg kg-1 increased the time of the 
retention session up to 77.9 ± 7.8 s (data not shown), while 7a was ineffective (Figure 12). 
  
Figure 12.  Passive avoidance test. Effects on learning and memory. All compounds were 
administered per os 30 min before the test. Scopolamine (1.5 mg kg-1 intraperitoneally) was 
administered immediately after the punishment. The time recorded during the retention session is 
reported. Each value represents the mean ± SEM of at least 10 mice. *P < 0.05 and **P < 0.01 in 
comparison to vehicle-treated mice. 
 
CONCLUSION 
 
The structural analogies existing between GABAA and 5-HT3 receptors stimulated the application of 
the approach we used in studying 5-HT3 receptors to the characterization of CBR interaction 
features. Thus, a series of imidazo[1,5-a]quinoline derivatives related to 5 (a previously described 
drug candidate for the treatment of anxiety) was designed, synthesized, and biologically 
characterized in comparison with reference imidazo[1,5-a]quinoxalines 10a-d. Most of the newly-
synthesized compounds showed high CBR affinity with Ki values in the submicromolar up to 
subnanomolar ranges and interesting SAR trends, which suggested the existence of a large although 
apparently saturable lipophilic pocket in the CBR binding site region interacting with positions 4 and 
5. From another perspective, this result could be interpreted as the evidence of a certain degree of 
conformational freedom of the amino acid residues interacting with the substituents in positions 4 
 and 5 of the imidazo[1,5-a]quinoline nucleus. Thus, this promising evidence paves the way to the 
application of our approach in studying the 5-HT3 receptor to the characterization of the interaction 
of CBR with divalent and more in general multivalent ligands.60 Fluoroderivative 7w (Ki = 0.44 nM) 
resulted the most potent ligand and despite its inverse agonist-antagonist profile suggested by its  
GABA ratio value of 0.8, acted as an agonist in light-dark box test, the classical animal model of 
anxiety, and was devoid of the undesired myorelaxant side effects. In addition, compound 7w (at 1 
mg kg-1) was found to significantly prevent scopolamine-induced amnesia showing the best efficacy 
among the compounds evaluated in the in vivo studies (7a,c,d,l,m,p,q,r). Furthermore, imidazo[1,5-
a]quinoline derivatives 7l (AB144P), 7q (AB151), 7r (AB152), and 8i (AB134) showed 
neuroprotective properties since they reduced LDH release induced by ischemia-like condition in an 
hormetic-like fashion although with different efficacy windows.  
 
EXPERIMENTAL SECTION  
Chemistry. All chemicals used were of reagent grade. Yields refer to purified products and are not 
optimized. Melting points were determined in open capillaries on a Gallenkamp apparatus and are 
uncorrected. Merck silica gel 60 (230-400 mesh) was used for column chromatography. Merck TLC 
plates, silica gel 60 F254 were used for TLC. NMR spectra were recorded by means of either a 
Bruker AC 200 or a Bruker DRX 400 AVANCE spectrometers in the indicated solvents (TMS as 
internal standard); the values of the chemical shifts are expressed in ppm and the coupling constants 
(J) in Hz.  
The purity of compounds 7a-aa, 8a-i, 9, and 10a-d was assessed by RP-HPLC and was found to 
be higher than 95%. An Agilent 1100 Series system equipped with a Phenomenex C18 (3.9 x 150 
mm, 10 m) column or a Zorbax Eclipse XBD-C8 (4.6 x 150 mm, 5 m) column was used in the 
HPLC analysis with acetonitrile-methanol-water (10:20:70) or (10:40:50) or (10:50:40) or 
(10:70:20) as the mobile phases at a flow rate of 2.0 mL/min. UV detection was achieved at 254 nm. 
Mass spectra were recorded on either a Thermo LCQ-Deca or an Agilent 1100 LC/MSD. 
 
 General procedure for the synthesis of target imidazo[1,5-a]quinoline derivatives 7a-i,k-m,o-y. 
A mixture of the suitable 2-chloroquinoline derivative (11-24, 1 equivalent) was cooled at 0-5 °C in 
dry DMF (typically, 10 mL for 1 mmol) under argon and then treated with the suitable 
isocyanoacetate (3 equivalents) and potassium tert-butoxide (3 equivalents). The resulting mixture 
was stirred at 0-5 °C for 30 min, then allowed to stir at room temperature for 1 h, and finally heated 
at 80 °C for 1-20 h (following the reaction progress by TLC). After cooling to room temperature, 
acetic acid (typically, 1.0 mL for 1 mmol) was added and the mixture was stirred for additional 20 
min and then poured onto crushed ice. The precipitate was collected by filtration, washed with 
water, dissolved into chloroform and the organic layer washed with brine, dried over Na2SO4, and 
concentrated under reduced pressure. The residue was purified by flash-chromatography with the 
suitable eluent to afford the expected imidazo[1,5-a]quinoline derivative (7a-i,k-m,o-y), which after 
re-crystallization from the suitable solvent gave an analytical sample. 
 
Ethyl 5-(dimethylcarbamoyl)imidazo[1,5-a]quinoline-3-carboxylate (7a). AB177  
The title compound was obtained as a white solid from 11 according to the above general procedure 
and purified by flash chromatography with ethyl acetate as the eluent (yield 35%). An analytical 
sample was obtained by recrystallization from ethyl acetate-chloroform by slow evaporation (white 
crystals, mp 209-210 °C). 1H NMR (400 MHz, CDCl3): 1.45 (t, J = 7.1, 3H), 2.96 (s, 3H), 3.23 (s, 
3H), 4.46 (q, J = 7.1, 2H), 7.52 (t, J = 7.6, 1H), 7.63-7.77 (m, 2H), 8.03 (s, 1H), 8.09 (d, J = 8.3, 
1H), 8.70 (s, 1H). 13C NMR (100 MHz, CDCl3): 14.5, 35.0, 38.9, 60.8, 115.3, 121.2, 125.6, 126.9, 
127.0, 128.4, 130.4, 130.6, 131.2, 132.7, 163.0, 168.0. MS (ESI): m/z 334 (M + Na+). 
 
tert-Butyl 5-(dimethylcarbamoyl)imidazo[1,5-a]quinoline-3-carboxylate (7b). AB178 
This compound was prepared from 11 according to the above general procedure and purified by 
flash chromatography with ethyl acetate as the eluent to obtain 7b as a white solid (yield 59%, mp 
222-223 °C). 1H NMR (400 MHz, CDCl3): 1.66 (s, 9H), 2.97 (s, 3H), 3.22 (s, 3H), 7.51 (t, J = 7.6, 
1H), 7.67 (t, J = 7.3, 1H), 7.71 (d, J = 8.0, 1H), 8.01 (s, 1H), 8.08 (d, J = 8.3, 1H), 8.66 (s, 1H). 13C 
 NMR (100 MHz, CDCl3): 28.4, 34.9, 38.9, 81.5, 115.3, 115.6, 121.2, 126.8, 127.0, 128.1, 130.2, 
130.6, 130.7, 132.2, 162.4, 168.1. MS (ESI): m/z 362 (M + Na+). 
 
Ethyl 5-[butyl(methyl)carbamoyl]imidazo[1,5-a]quinoline-3-carboxylate (7c). AB180  
This compound was synthesized from 12 according to the above general procedure and purified by 
flash chromatography with ethyl acetate/n-hexane (9:1) as the eluent to obtain 7c as a white solid 
(yield 10%, mp 148-149 °C). Since the amide nitrogen of the compound bears two different 
substituents, its 1H NMR spectrum (CDCl3) shows the presence of a (ca. 1:1) mixture of two 
rotamers in equilibrium; for the sake of simplification, the integral values have not been reported. 1H 
NMR (400 MHz, CDCl3): 0.73 (t, J = 7.3), 1.03 (t, J = 7.3), 1.07-1.19 (m), 1.42-1.58 (m), 1.67-1.78 
(m), 2.92 (s), 3.18-3.25 (m), 3.61-3.69 (m), 4.47 (q, J = 7.1), 7.50-7.57 (m), 7.66-7.77 (m), 8.02 (s), 
8.03 (s), 8.10 (d, J = 8.3), 8.71 (s), 8.72 (s). MS (ESI): m/z 376 (M + Na+). 
 
tert-Butyl 5-[butyl(methyl)carbamoyl]imidazo[1,5-a]quinoline-3-carboxylate (7d). AB181 
This compound was prepared from 12 according to the above general procedure and purified by 
flash chromatography with ethyl acetate/n-hexane (9:1) as the eluent to obtain 7d as a creamy solid 
(yield 17%, mp 148-150 °C). Since the amide nitrogen of the compound bears two different 
substituents, its 1H NMR spectrum (CDCl3) shows the presence of a (ca. 1:1) mixture of two 
rotamers in equilibrium; for the sake of simplification, the integral values have not been reported. 1H 
NMR (400 MHz, CDCl3): 0.73 (t, J = 7.3), 1.01 (t, J = 7.3), 1.07-1.18 (m), 1.38-1.77 (m), 2.14 (s), 
2.92 (s), 3.18 (s), 3.19-3.24 (m), 3.64 (t, J = 7.5), 7.47-7.54 (m), 7.63-7.73 (m), 7.97 (s), 8.08 (d, J = 
8.3), 8.68 (s), 8.69 (s). MS (ESI): m/z 404 (M + Na+). 
 
 Ethyl 5-(dipropylcarbamoyl)imidazo[1,5-a]quinoline-3-carboxylate (7e). AB144A 
The title compound was prepared from 1338 according to the above general procedure and purified 
by flash chromatography with n-hexane-ethyl acetate (1:1) as the eluent to obtain 7e as a white solid 
(yield 72%, mp 168-169 °C). 1H NMR (400 MHz, CDCl3): 0.71 (t, J = 7.4, 3H), 1.04 (t, J = 7.4, 
 3H), 1.44 (t, J = 7.1, 3H), 1.48-1.59 (m, 2H), 1.72-1.87 (m, 2H), 3.15 (br s, 2H), 3.57 (br s, 2H), 4.46 
(q, J = 7.1, 2H), 7.50 (t, J = 7.7, 1H), 7.63-7.69 (m, 1H), 7.72 (d, J = 8.1, 1H), 7.99 (s, 1H), 8.08 (d, 
J = 8.3, 1H), 8.68 (s, 1H). MS (ESI): m/z 368 (M + H+). 
 
tert-Butyl 5-(dipropylcarbamoyl)imidazo[1,5-a]quinoline-3-carboxylate (7f). AB147 
The title compound was prepared from 1338 according to the above general procedure and purified 
by flash chromatography with n-hexane-ethyl acetate (1:1) as the eluent to obtain 7f as a white solid 
(yield 48%, mp 159-160 °C). 1H NMR (400 MHz, CDCl3): 0.72 (t, J = 7.4, 3H), 1.05 (t, J = 7.4, 
3H), 1.37-1.96 (m, 13H), 3.17 (br s, 2H), 3.57 (br s, 2H), 7.52 (t, J = 7.7, 1H), 7.64-7.70 (m, 1H), 
7.72 (d, J = 8.0, 1H), 7.96 (s, 1H), 8.08 (d, J = 8.3, 1H), 8.71 (s, 1H). MS (ESI): m/z 418 (M + Na+). 
 
Ethyl 5-[benzyl(methyl)carbamoyl]imidazo[1,5-a]quinoline-3-carboxylate (7g). AB174  
The title compound was prepared from 1438 according to the above general procedure and purified 
by flash chromatography with ethyl acetate as the eluent to obtain 7g as a white solid (yield 56%). 
An analytical sample was obtained by recrystallization from ethyl acetate-chloroform by slow 
evaporation (mp 198-199 °C).  Since the amide nitrogen of the compound bears two different 
substituents, its 1H NMR spectrum (CDCl3) shows the presence of a (ca. 6:4) mixture of two 
rotamers in equilibrium; for the sake of simplification, the integral values have not been reported. 1H 
NMR (400 MHz, CDCl3): 1.39-1.49 (m), 2.84 (s), 3.14 (s), 4.38-4.51 (m), 4.86 (s), 7.10 (d, J = 7.0), 
7.20-7.46 (m), 7.47-7.56 (m), 7.63-7.70 (m), 7.73 (d, J = 8.0), 7.82 (d, J = 8.0), 8.04-8.13 (m), 8.66 
(s), 8.67 (s). MS (ESI): m/z 388 (M + H+). 
 
tert-Butyl 5-[benzyl(methyl)carbamoyl]imidazo[1,5-a]quinoline-3-carboxylate (7h). AB175  
The title compound was synthesized from 1438 according to the above general procedure and 
purified by flash chromatography with ethyl acetate as the eluent to obtain 7h as a white solid (yield 
36%, mp 92-93 °C). Since the amide nitrogen of the compound bears two different substituents, its 
1H NMR spectrum (CDCl3) shows the presence of a (ca. 6:4) mixture of two rotamers in 
 equilibrium; for the sake of simplification, the integral values have not been reported. 1H NMR (400 
MHz, CDCl3): 1.65 (s), 1.66 (s), 2.86 (s), 3.14 (s), 4.48 (s), 4.86 (s), 7.11 (d, J = 7.0), 7.19-7.46 (m), 
7.49-7.59 (m), 7.64-7.72 (m), 7.75 (d, J = 8.0), 7.82 (d, J = 8.0), 8.00-8.12 (m), 8.70 (s). MS (ESI): 
m/z 438 (M + Na+). 
 
Ethyl 5-(4-methylpiperazine-1-carbonyl)imidazo[1,5-a]quinoline-3-carboxylate (7i). AB146 
The title compound was prepared from 1540 according to the above general procedure and purified 
by flash chromatography with ethyl acetate-triethylamine (8:2) as the eluent to obtain 7i as a white 
solid (yield 25%, mp 230-231 °C). 1H NMR (400 MHz, CDCl3): 1.44 (t, J = 7.1, 3H), 2.19-2.43 (m, 
5H), 2.57 (br s, 2H), 3.24-3.53 (br m, 2H), 3.93 (br s, 2H), 4.46 (q, J = 7.0, 2H), 7.52 (t, J = 7.7, 1H), 
7.67 (t, J = 7.8, 1H), 7.75 (d, J = 8.0, 1H), 8.02 (s, 1H), 8.07 (d, J = 8.3, 1H), 8.64 (s, 1H). 13C NMR 
(100 MHz, CDCl3): 14.5, 41.7, 45.9, 47.1, 54.7, 55.3, 60.7, 115.3, 121.3, 125.9, 126.9, 128.4, 130.4, 
130.6, 131.1, 131.9, 163.1, 166.5. MS (ESI): m/z 367 (M + H+).  
Anal. calcd for C20H22N4O3: C, 65.56; H, 6.05; N, 15.29, found: C, 65.67; H, 6.44; N, 15.39. 
 
5-tert-Butyl 3-ethyl 4-methylimidazo[1,5-a]quinoline-3,5-dicarboxylate (7k). AB166 
The title compound was prepared from 16 according to the above general procedure and purified by 
flash chromatography with ethyl acetate-n-hexane (8:2) as the eluent to obtain 7k as a white solid 
(yield 94%, mp 197-200 °C). 1H NMR (400 MHz, CDCl3): 1.47 (t, J = 7.1, 3H), 1.68 (s, 9H), 2.78 
(s, 3H), 4.46 (q, J = 7.1, 2H), 7.52 (t, J = 7.6, 1H), 7.61-7.69 (m, 2H), 8.09 (d, J = 8.3, 1H), 8.89 (s, 
1H). MS (ESI): m/z 355 (M + H+). 
 
Ethyl 5-(dipropylcarbamoyl)-4-methylimidazo[1,5-a]quinoline-3-carboxylate (7l). AB144P  
The title compound was prepared from 1738 according to the above general procedure and purified 
by flash chromatography with ethyl acetate as the eluent to obtain 7l as a off-white solid (yield 60%, 
mp 173-174 °C). 1H NMR (400 MHz, CDCl3): 0.65 (t, J = 7.2, 3H), 1.05 (t, J = 7.2, 3H), 1.32-1.56 
(m, 5H), 1.74-1.89 (m, 2H), 2.71 (s, 3H), 2.98-3.17 (m, 2H), 3.45-3.72 (m, 2H), 4.43 (q, J = 7.2, 
 2H), 7.44 (t, J = 7.5, 1H), 7.52-7.62 (m, 2H), 8.03 (d, J = 8.3, 1H), 8.70 (s, 1H).  MS (ESI): m/z 382 
(M + H+).  
Anal. Calcd for C22H27N3O3: C, 69.27; H, 7.13; N, 11.02, found: C, 69.13; H, 7.34; N, 11.19. 
 
tert-Butyl 5-(dipropylcarbamoyl)-4-methylimidazo[1,5-a]quinoline-3-carboxylate (7m). AB145  
The title compound was prepared from 1738 according to the above general procedure and purified 
by flash chromatography with ethyl acetate as the eluent to obtain 7m as a white solid (yield 46%, 
mp 138-139 °C). 1H NMR (400 MHz, CDCl3): 0.66 (t, J = 7.4, 3H), 1.05 (t, J = 7.4, 3H), 1.31-1.55 
(m, 2H), 1.66 (s, 9H), 1.75-1.90 (m, 2H), 2.66 (s, 3H), 2.99-3.18 (m, 2H), 3.45-3.56 (m, 1H), 3.62-
3.74 (m, 1H), 7.45 (t, J = 7.6, 1H), 7.53-7.63 (m, 2H), 8.01 (d, J = 8.3, 1H), 8.65 (s, 1H).  MS (ESI): 
m/z 432 (M + Na+).  
Anal. Calcd for C24H31N3O3: C, 70.39; H, 7.63; N, 10.26, found: C, 70.22; H, 7.44; N, 10.23. 
 
Ethyl 5-[benzyl(methyl)carbamoyl]-4-methylimidazo[1,5-a]quinoline-3-carboxylate (7o). 
AB169 
The title compound was prepared from 1838 according to the above general procedure and purified 
by flash chromatography with ethyl acetate-n-hexane (8:2) as the eluent to obtain 7o as a white solid 
(yield 26%, mp 214-215 °C). The 1H NMR spectrum (CDCl3) of the compound shows the presence 
of the minor rotamer only in trace amounts. For the sake of simplification, only the signals of the 
major rotamer have been reported. 1H NMR (400 MHz, CDCl3): 1.44 (t, J = 7.1, 3H), 2.70 (s, 3H), 
2.75 (s, 3H), 4.42 (q, J = 7.1, 2H), 4.79 (d, J = 14.1, 1H), 4.99 (d, J = 14.1, 1H), 7.30-7.61 (m, 8H), 
8.02 (d, J = 8.3, 1H), 8.69 (s, 1H).  MS (ESI): m/z 402 (M + H+).  
 
tert-Butyl 5-[benzyl(methyl)carbamoyl]-4-methylimidazo[1,5-a]quinoline-3-carboxylate (7p). 
AB172 
The title compound was prepared from 1838 according to the above general procedure and purified 
by flash chromatography with ethyl acetate-n-hexane (8:2) as the eluent to obtain 7p as a white solid 
 (yield 46%, mp 123-126 °C). The 1H NMR spectrum (CDCl3) of the compound shows the presence 
of the minor rotamer only in trace amounts. For the sake of simplification, only the signals of the 
major rotamer have been reported. 1H NMR (400 MHz, CDCl3): 1.64 (s, 9H), 2.64 (s, 3H), 2.74 (s, 
3H), 4.74 (d, J = 14.1, 1H), 5.01 (d, J = 14.1, 1H), 7.29-7.58 (m, 8H), 7.99 (d, J = 8.3, 1H), 8.65 (s, 
1H). MS (ESI): m/z 430 (M + H+). 
 
Ethyl 5-(dipropylcarbamoyl)-4-ethylimidazo[1,5-a]quinoline-3-carboxylate (7q). AB151 
The title compound was prepared from 1938 according to the above general procedure and purified 
by flash chromatography with ethyl acetate-n-hexane (7:3) as the eluent to obtain 7q as a white solid 
(yield 27%, mp 114-115 °C). 1H NMR (400 MHz, CDCl3): 0.65 (t, J = 7.4, 3H), 1.06 (t, J = 7.4, 
3H), 1.21 (t, J = 7.4, 3H), 1.33-1.57 (m, 5H), 1.74-1.90 (m, 2H), 2.74-2.88 (m, 1H), 2.96-3.16 (m, 
2H), 3.46-3.59 (m, 1H), 3.61-3.78 (m, 2H), 4.38-4.55 (m, 2H), 7.48 (t, J = 7.6, 1H), 7.55-7.65 (m, 
2H), 8.06 (d, J = 8.3, 1H), 8.79 (s, 1H). MS (ESI): m/z 418 (M + Na+).  
Anal. calcd for C23H29N3O3 x 0.25 H2O: C, 69.06; H, 7.43; N, 10.51, found: C, 69.14; H, 7.50; N, 
10.25. 
 
tert-Butyl 5-(dipropylcarbamoyl)-4-ethylimidazo[1,5-a]quinoline-3-carboxylate (7r). AB152  
The title compound was prepared from 1938 according to the above general procedure and purified 
by flash chromatography with ethyl acetate-n-hexane (8:2) as the eluent to obtain 7r as white 
crystals (yield 15%, mp 160-161 °C). 1H NMR (400 MHz, CDCl3): 0.65 (t, J = 7.4, 3H), 1.05 (t, J = 
7.4, 3H), 1.18 (t, J = 7.4, 3H), 1.30-1.56 (m, 2H), 1.67 (s, 9H), 1.76-1.89 (m, 2H), 2.71-2.77 (m, 
1H), 2.97-3.15 (m, 2H), 3.46-3.57 (m, 1H), 3.61-3.72 (m, 2H), 7.45 (t, J = 7.6, 1H), 7.52-7.61 (m, 
2H), 8.02 (d, J = 8.3, 1H), 8.67 (s, 1H). MS (ESI): m/z 446 (M + Na+).  
Anal. calcd for C25H33N3O3: C, 70.89; H, 7.85; N, 9.92, found: C, 71.18; H, 8.15; N, 9.82. 
 
Ethyl 5-(diethylcarbamoyl)-4-propylimidazo[1,5-a]quinoline-3-carboxylate (7s). AB160  
 The title compound was prepared from 2038 according to the above general procedure and purified 
by flash chromatography with ethyl acetate-n-hexane (8:2) as the eluent to obtain 7s as a white solid 
(yield 21%). An analytical sample was obtained by recrystallization from diethyl ether by slow 
evaporation (X-ray quality pale yellow crystals, mp 103-104 °C). 1H NMR (400 MHz, CDCl3): 0.92-
1.07 (m, 6H), 1.36 (t, J = 7.1, 3H), 1.43 (t, J = 7.1, 3H), 1.50-1.67 (m, 2H), 2.61-2.79 (m, 1H), 3.07-
3.30 (m, 2H), 3.50-3.69 (m, 2H), 3.75-3.89 (m, 1H), 4.35-4.53 (m, 2H), 7.43 (t, J = 7.5, 1H), 7.52-
7.60 (m, 2H), 8.01 (d, J = 8.2, 1H), 8.67 (s, 1H). 13C NMR (100 MHz, CDCl3): 12.7, 14.0, 14.1, 
14.5, 23.6, 33.1, 38.9, 43.0, 61.1, 114.9, 121.6, 126.3, 126.6, 127.2, 128.0, 128.5, 129.2, 129.5, 
130.4, 130.7, 163.4, 167.3. MS (ESI): m/z 382 (M + H+).  
Anal. calcd for C22H27N3O3: C, 69.27; H, 7.13; N, 11.02, found: C, 69.45; H, 7.40; N, 11.05. 
 
tert-Butyl 5-(diethylcarbamoyl)-4-propylimidazo[1,5-a]quinoline-3-carboxylate (7t). AB161 
The title compound was prepared from 2038 according to the above general procedure and purified 
by flash chromatography with ethyl acetate-n-hexane (8:2) as the eluent to obtain 7t as a white solid 
(yield 55%). An analytical sample was obtained by recrystallization from diethyl ether by slow 
evaporation (X-ray quality pale yellow prisms, mp 142-143 °C). 1H NMR (400 MHz, CDCl3): 0.89-
1.05 (m, 6H), 1.35 (t, J = 7.0, 3H), 1.48-1.58 (m, 2H), 1.64 (s, 9H), 2.55-2.74 (m, 1H), 3.07-3.31 (m, 
2H), 3.50-3.65 (m, 2H), 3.72-3.85 (m, 1H), 7.41 (t, J = 7.5, 1H), 7.51-7.61 (m, 2H), 7.99 (d, J = 8.2, 
1H), 8.63 (s, 1H). 13C NMR (100 MHz, CDCl3): 12.7, 14.0, 23.2, 28.3, 32.9, 38.9, 43.0, 81.5, 114.8, 
121.6, 126.3, 126.4, 127.7, 128.5, 129.0, 129.1, 129.2, 129.5, 130.0, 163.3, 167.4. MS (ESI): m/z 
432 (M + Na+).  
Anal. calcd for C24H31N3O3: C, 70.39; H, 7.63; N, 10.26, found: C, 70.62; H, 7.90; N, 10.00. 
 
Ethyl 5-(dipropylcarbamoyl)-4-propylimidazo[1,5-a]quinoline-3-carboxylate (7u). AB157 
The title compound was prepared from 2138 according to the above general procedure and purified 
by flash chromatography with ethyl acetate-n-hexane (8:2) as the eluent to obtain 7u as a white solid 
(yield 5%, mp 143-144 °C). 1H NMR (400 MHz, CDCl3): 0.63 (t, J = 7.1, 3H), 0.98 (t, J = 7.0, 3H), 
 1.04 (t, J = 7.1, 3H), 1.31-1.51 (m, 5H), 1.53-1.64 (m, 2H), 1.74-1.89 (m, 2H), 2.58-2.72 (m, 1H), 
2.98-3.16 (m, 2H), 3.37-3.51 (m, 1H), 3.60-3.81 (m, 2H), 4.38-4.52 (m, 2H), 7.43 (t, J = 7.4, 1H), 
7.51-7.63 (m, 2H), 8.01 (d, J = 7.9, 1H), 8.69 (s, 1H). 13C NMR (100 MHz, CDCl3): 11.3, 11.7, 14.1, 
14.5, 20.6, 21.7, 23.6, 33.2, 46.4, 50.6, 61.1, 114.8, 121.6, 126.5, 127.2, 128.0, 128.5, 129.2, 129.5, 
130.4, 130.7, 163.4, 167.7. MS (ESI): m/z 410 (M + H+).  
Anal. calcd for C24H31N3O3: C, 70.39; H, 7.63; N, 10.26, found: C, 70.01; H, 7.83; N, 10.21. 
 
tert-Butyl 5-(dipropylcarbamoyl)-4-propylimidazo[1,5-a]quinoline-3-carboxylate (7v). AB158 
The title compound was prepared from 2138 according to the above general procedure and purified 
by flash chromatography with ethyl acetate-n-hexane (8:2) as the eluent to obtain 7v as a white solid 
(yield 4%, mp 163-164 °C). 1H NMR (400 MHz, CDCl3): 0.64 (t, J = 6.5, 3H), 0.96 (t, J = 6.3, 3H), 
1.04 (t, J = 6.5, 3H), 1.32-1.93 (m, 15H), 2.46-2.69 (m, 1H), 2.94-3.22 (m, 2H), 3.33-3.51 (m, 1H), 
3.58-3.85 (m, 2H), 7.42 (t, J = 6.9, 1H), 7.51-7.62 (m, 2H), 8.00 (d, J = 7.9, 1H), 8.64 (s, 1H). 13C 
NMR (100 MHz, CDCl3): 11.3, 11.7, 14.0, 20.6, 21.8, 23.2, 28.3, 33.0, 46.4, 50.6, 81.5, 114.8, 
121.6, 126.4, 126.5, 127.6, 128.5, 129.0, 129.1, 129.2, 129.5, 130.0, 163.3, 167.8. MS (ESI): m/z 
438 (M + H+).  
Anal. calcd for C26H35N3O3: C, 71.37; H, 8.06; N, 9.60, found: C, 71.70; H, 8.25; N, 9.46. 
 
Ethyl 5-(dipropylcarbamoyl)-7-fluoroimidazo[1,5-a]quinoline-3-carboxylate (7w). AB188 
The title compound was prepared from 22 according to the above general procedure and purified by 
flash chromatography with n-hexane-ethyl acetate (1:1) as the eluent to obtain 7w as a off-white 
solid (yield 21%, mp 175-177 °C). 1H NMR (400 MHz, CDCl3): 0.71 (t, J = 7.3, 3H), 1.03 (t, J = 
7.3, 3H), 1.43 (t, J = 7.1, 3H), 1.47-1.59 (m, 2H), 1.72-1.85 (m, 2H), 3.09-3.22 (m, 2H), 3.55 (br s, 
2H), 4.45 (q, J = 7.1, 2H), 7.33-7.42 (m, 2H), 8.02 (s, 1H), 8.05-8.13 (m, 1H), 8.62 (s, 1H). MS 
(ESI): m/z 408 (M + Na+). 
 
Ethyl 5-[benzyl(methyl)carbamoyl]-7-fluoroimidazo[1,5-a]quinoline-3-carboxylate (7x). AB186 
 The title compound was prepared from 23 according to the above general procedure and purified by 
flash chromatography with ethyl acetate-n-hexane (8:2) as the eluent to obtain 7x as a white solid 
(yield 15%). An analytical sample was obtained by recrystallization from ethyl acetate-
dichlorometane by slow evaporation (mp 180-182 °C).  Since the amide nitrogen of the compound 
bears two different substituents, its 1H NMR spectrum (CDCl3) shows the presence of a (ca. 6:4) 
mixture of two rotamers in equilibrium; for the sake of simplification, the integral values have not 
been reported. 1H NMR (400 MHz, CDCl3): 1.39-1.52 (m), 2.87 (s), 3.16 (s), 4.36-4.49 (m), 4.50 (s), 
4.86 (s), 7.11 (d, J = 7.1), 7.21-7.55 (m), 8.04-8.10 (m), 8.11 (s), 8.14 (s), 8.62 (s), 8.63 (s). MS 
(ESI): m/z 406 (M + H+). 
 
Ethyl 5-[benzyl(methyl)carbamoyl]-7-bromoimidazo[1,5-a]quinoline-3-carboxylate (7y). 
AB197  
The title compound was prepared from 24 according to the above general procedure (with the 
exception that the reaction was carried out at 0-5 °C for 2 h and then at room temperature for 2 h) 
and purified by flash chromatography with ethyl acetate-petroleum ether (7:3) as the eluent to obtain 
7y as a white solid (yield 62%, mp 177-178 °C). Since the amide nitrogen of the compound bears 
two different substituents, its 1H NMR spectrum (CDCl3) shows the presence of a (ca. 6:4) mixture 
of two rotamers in equilibrium; for the sake of simplification, the integral values have not been 
reported. 1H NMR (400 MHz, CDCl3): 1.32-1.49 (m), 2.86 (s), 3.18 (s), 4.34-4.57 (m), 4.87 (s), 
7.09-7.12 (m), 7.22-7.54 (m), 7.78 (d, J = 8.2), 7.86-8.16 (m), 8.63 (s). MS (ESI): m/z 466, 468 (M + 
H+). 
 
2-Chloro-N,N-dimethylquinoline-4-carboxamide (11). AB176 
This compound was prepared from of 2-hydroxy-4-quinolinecarboxylic acid and dimethylamine 
by following the procedure described in ref 38 and was purified by flash chromatography with n-
hexane-ethyl acetate (1:1) as the eluent (yield 39%). 1H NMR (200 MHz, CDCl3): 2.84 (s, 3H), 3.25 
 (s, 3H), 7.31 (s, 1H), 7.55-7.62 (m, 1H), 7.73-7.80 (m, 2H), 8.06 (d. J = 8.3, 1H). MS (ESI): m/z 257 
(M + Na+). 
 
N-Butyl-2-chloro-N-methylquinoline-4-carboxamide (12). AB179 
This compound was prepared from of 2-hydroxy-4-quinolinecarboxylic acid and N-
methylbutylamine by following the procedure described in ref 38 and was purified by flash 
chromatography with n-hexane-ethyl acetate (9:1) as the eluent (yield 81%, mp 86-87 °C). Since the 
amide nitrogen of this compound bears two different substituents, its 1H NMR spectrum shows the 
presence of two different rotamers in equilibrium; for the sake of simplification the integral 
intensities have not been given. 1H NMR (200 MHz, CDCl3): 0.70 (t, J = 7.2), 0.98-1.17 (m), 1.37-
1.55 (m), 1.65-1.79 (m), 2.78 (s), 3.04 (t, J = 7.5), 3.19 (s), 3.64 (t, J = 7.5), 7.28 (s), 7.53-7.61 (m), 
7.71-7.78 (m), 8.04 (d. J = 8.2). MS (ESI): m/z 277 (M + H+). 
 
tert-Butyl 2-chloro-3-methylquinoline-4-carboxylate (16). AB165 
To a solution of acid chloride 25 (3.5 g, 14.6 mmol, ref 38) in dry THF (15 mL) cooled at 0-5 °C 
was added a mixture of potassium tert-butoxide (1.64 g, 14.6 mmol) in 15 mL of dry THF. The 
resulting mixture was stirred at the same temperature for 10 min and at room temperature for 30 
min. The reaction mixture was then poured into crushed ice and the precipitate was collected by 
filtration, dried under reduced pressure and purified by flash chromatography with petroleum ether-
ethyl acetate (9:1) as the eluent to obtain 16 as a white solid (3.4 g, yield 84%). An analytical sample 
was obtained by recrystallization from n-hexane (mp 107-108 °C). 1H NMR (400 MHz, CDCl3): 
1.69 (s, 9H), 2.52 (s, 3H), 7.56 (t, J = 7.6, 1H); 7.67-7.74 (m, 2H), 7.99 (d, J = 8.4, 1H). MS (ESI): 
m/z 278 (M + H+). 
 
3-(Ethoxycarbonyl)-4-methylimidazo[1,5-a]quinoline-5-carboxylic acid (7j). AB168 
A mixture of 7k (0.37 g, 1.04 mol) in formic acid (15 mL) was stirred at room temperature 
overnight and then concentrated under reduced pressure. Purification of the residue by washing with 
 diethyl ether afforded acid 7j as a white solid (0.29 g, yield 93%, mp dec. > 300 °C). 1H NMR (400 
MHz, DMSO-d6): 1.31 (t, J = 7.0, 3H), 2.59 (s, 3H), 4.30 (q, J = 7.0, 2H), 7.57 (t, J = 7.5, 1H), 7.64 
(d, J = 7.8, 1H), 7.71 (t, J = 7.5, 1H), 8.52 (d, J = 8.3, 1H), 9.28 (s, 1H). MS (ESI, negative ions): 
m/z 297 (M - H+). 
 
Ethyl 4-methyl-5-[methyl(prop-2-ynyl)carbamoyl]imidazo[1,5-a]quinoline-3-carboxylate 
(7n). AB171 
A mixture of acid 7j (0.80 g, 2.68 mmol) in 6.0 mL of thionyl chloride was heated to reflux for 3 h 
and then concentrated under reduced pressure. The residue was dissolved into 6.0 mL of 
dichloromethane and the resulting solution was treated with N-methylpropargylamine (0.43 mL, 5.1 
mmol). The reaction mixture was stirred at room temperature for 30 min and then partitioned 
between dichloromethane and water. The organic layer was washed with water, dried over sodium 
sulfate and concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography with n-hexane-ethyl acetate (1:1) as the eluent to obtain 7n as a white solid (0.82 g, 
yield 88%, mp 219-220 °C). The 1H NMR spectrum (CDCl3) of the compound shows the presence 
of the minor rotamer only in low amount. For the sake of simplification, only the signals of the 
major rotamer have been reported. 1H NMR (400 MHz, CDCl3): 1.46 (t, J = 7.1, 3H), 2.34 (br s, 
1H), 2.72 (s, 3H), 2.94 (s, 3H), 4.38-4.51 (m, 3H), 4.59 (d, J = 17.2, 1H), 7.45-7.51 (m, 1H), 7.55 (d, 
J = 8.0, 1H), 7.62 (t, J = 7.7, 1H), 8.04 (d, J = 8.3, 1H), 8.68 (s, 1H). MS (ESI): m/z 350 (M + H+). 
 
2-Chloro-6-fluoro-4-quinolinecarboxylic acid (27a). AB184 
A mixture of 6-fluoro-2-hydroxy-4-quinolinecarboxylic acid (26a,41 3.0 g, 14.5 mmol) in 15 mL of 
POCl3 was heated to reflux for 2 h and then poured into crushed ice. The precipitate was extracted 
with chloroform and the organic layer was dried over sodium sulfated and concentrated under 
reduced pressure. Purification of the residue by washing with n-hexane gave acid 27a (2.3 g, yield 
70%), which was promptly used in the subsequent step. 1H NMR (200 MHz, DMSO-d6): 7.75-7.85 
(m, 1H), 7.97 (s, 1H), 8.06-8.14 (m, 1H), 8.39-8.46 (m, 1H), 14.20 (br s, 1H). 
  
6-Bromo-2-chloro-4-quinolinecarboxylic acid (27b). AB195 
A mixture of 6-bromo-2-hydroxy-4-quinolinecarboxylic acid (26b, Aldrich CPR) (1.0 g, 3.7 
mmol) in 10 mL of POCl3 was heated to reflux for 3 h and then poured into crushed ice. The 
precipitate was extracted with ethyl acetate and the organic layer was dried over sodium sulfated and 
concentrated under reduced pressure. Purification of the residue by washing with n-hexane gave acid 
27b (1.0 g, yield 94%), which was promptly used in the subsequent step. 1H NMR (200 MHz, 
DMSO-d6): 7.95 (m, 3H), 8.89 (s, 1H). MS (ESI, negative ions): m/z 284, 286, 288 (M - H
+). 
 
2-Chloro-N,N-dipropylquinoline-6-fluoro-4-carboxamide (22). AB187 
A mixture of acid 27a (1.0 g, 4.43 mmol) in thionyl chloride (5.0 mL) was refluxed under argon 
for 2 h. The thionyl chloride excess was then removed under reduced pressure and the resulting acid 
chloride was immediately used without further purification. To a mixture of acid chloride in 20 mL 
of dichloromethane cooled at 0-5 °C was added dipropylamine (0.57 mL, 4.16 mmol) and 
triethylamine (TEA, 1.0 mL) and the resulting mixture was stirred at room temperature for 30 min 
while the reaction progress was monitored by TLC. The reaction mixture was concentrated under 
reduced pressure and partitioned between CH2Cl2 and water. The organic layer was dried over 
sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography with n-hexane-ethyl acetate (8:2) as the eluent to obtain 22 as pale yellow oil, 
which slowly crystallized on standing (1.1 g, yield 86%). 1H NMR (200 MHz, CDCl3): 0.67 (t, J = 
7.3, 3H), 1.02 (t, J = 7.3, 3H), 1.37-1.56 (m, 2H), 1.67-1.86 (m, 2H), 2.99 (t, J = 7.3, 2H), 3.54 (br s, 
2H), 7.26-7.37 (m, 2H), 7.45-7.55 (m, 1H), 7.98-8.05 (m, 1H). MS (ESI): m/z 309 (M + H+). 
 
N-Benzyl-2-chloro-6-fluoro-N-methylquinoline-4-carboxamide (23). AB185 
A mixture of acid 27a (1.0 g, 4.43 mmol) in thionyl chloride (5.0 mL) was refluxed under argon 
for 2 h. The thionyl chloride excess was then removed under reduced pressure and the resulting acid 
chloride was immediately used without further purification. To a mixture of acid chloride in 20 mL 
 of dichloromethane cooled at 0-5 °C was added N-methylbenzylamine (0.53 mL, 4.11 mmol) and 
TEA (1.0 mL) and the resulting mixture was stirred at room temperature for 30 min while the 
reaction progress was monitored by TLC. The reaction mixture was concentrated under reduced 
pressure and partitioned between CH2Cl2 and water. The organic layer was dried over sodium sulfate 
and concentrated under reduced pressure. The resulting residue was purified by flash 
chromatography with n-hexane-ethyl acetate (7:3) as the eluent to obtain 23 as pale yellow oil, 
which slowly crystallized on standing (1.1 g, yield 81%, mp 97-98 °C). Since the amide nitrogen of 
this compound bears two different substituents, its 1H NMR spectrum shows the presence of two 
different rotamers in equilibrium; for the sake of simplification the integral intensities have not been 
given. 1H NMR (200 MHz, CDCl3): 2.69 (s), 3.12 (s), 4.28 (s), 4.80 (s), 6.98-7.01 (m), 7.23-7.50 
(m), 7.94-8.01 (m). MS (ESI): m/z 329 (M + H+). 
 
N-Benzyl-6-bromo-2-chloro-N-methylquinoline-4-carboxamide (24). AB196 
A mixture of acid 27b (1.3 g, 4.54 mmol) in dichloromethane (20 mL) and thionyl chloride (5.0 
mL) was refluxed under argon for 3 h. The volatile was then removed under reduced pressure and 
the resulting acid chloride was immediately used without further purification. To a mixture of acid 
chloride in 20 mL of dichloromethane cooled at 0-5 °C was added N-methylbenzylamine (1.2 mL, 
9.3 mmol) and TEA (1.0 mL) and the resulting mixture was stirred at room temperature for 30 min 
while the reaction progress was monitored by TLC. The reaction mixture was washed with water, 
dried over sodium sulfate, and concentrated under reduced pressure. The resulting residue was 
purified by flash chromatography with n-hexane-ethyl acetate (7:3) as the eluent to obtain 24 as a 
white solid (1.0 g, yield 57%, mp 127-128 °C). Since the amide nitrogen of this compound bears two 
different substituents, its 1H NMR spectrum shows the presence of two different rotamers in 
equilibrium; for the sake of simplification the integral values have not been given. 1H NMR (200 
MHz, CDCl3): 2.73 (s), 3.19 (s), 4.31 (s), 4.86 (s), 7.02-7.06 (m), 7.29-7.45 (m), 7.78-7.97 (m). MS 
(ESI): m/z 389, 391, 393 (M + H+). 
 
 Ethyl 5-[benzyl(methyl)carbamoyl]-7-[(trimethylsilyl)ethynyl]imidazo[1,5-a]quinoline-3-
carboxylate (7aa). AB198 
To a solution of 7y (25 mg, 0.0536 mmol) in dry TEA (5.0 mL), ethynyltrimethylsilane (0.045 
mL, 0.32 mmol) and Pd(PPh3)2(OAc)2 (4.0 mg, 0.0053 mmol) were added. The reaction mixture was 
allowed to stir at room temperature for 30 min, then refluxed for 20 h, and finally filtered and 
concentrated under reduced pressure. The residue was dissolved in dichloromethane and the organic 
layer was washed with a saturated solution of sodium bicarbonate, dried over sodium sulfate and 
concentrated under reduced pressure. Purification of the residue by flash chromatography with ethyl 
acetate-n-hexane (7:3) as the eluent gave 7aa as an oil which slowly crystallized on standing (12 mg, 
yield 46%). Since the amide nitrogen of this compound bears two different substituents, its 1H NMR 
spectrum shows the presence of a (ca. 6:4) mixture of two different rotamers in equilibrium; for the 
sake of simplification the integral values have not been given. 1H NMR (400 MHz, CDCl3): 0.29 (s), 
1.38-1.48 (m), 2.86 (s), 3.19 (s), 4.36-4.55 (m), 4.88 (s), 7.13 (d, J = 7.5), 7.18-7.50 (m), 7.75 (d, J = 
8.7), 7.83 (s), 7.90 (s), 7.95-8.12 (m), 8.61 (s), 8.62 (s). MS (ESI): m/z 484 (M + H+). 
 
Ethyl 5-[benzyl(methyl)carbamoyl]-7-ethynylimidazo[1,5-a]quinoline-3-carboxylate (7z). 
AB199 
To a solution of 7aa (50 mg, 0.103 mmol) in THF (15 mL), a solution (1M in THF) of Bu4NF 
(0.12 mL, 0.12 mmol) was added. The reaction mixture was stirred at room temperature for 1 h, then 
diluted with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried 
over sodium sulfate and concentrated under reduced pressure. Purification of the residue by flash 
chromatography with ethyl acetate as the eluent gave 7z as a yellow glassy solid (21 mg, yield 49%). 
Since the amide nitrogen of this compound bears two different substituents, its 1H NMR spectrum 
shows the presence of a (ca. 6:4) mixture of two different rotamers in equilibrium; for the sake of 
simplification the integral values have not been given. 1H NMR (400 MHz, CDCl3): 1.39-1.49 (m), 
2.86 (s), 3.18 (s), 3.19 (s), 3.22 (s), 4.40-4.51 (m), 4.87 (s), 7.12 (d, J = 7.2), 7.22-7.49 (m), 7.77 (d, 
J = 8.2), 7.88 (s), 7.95 (s), 7.98-8.12 (m), 8.63 (s), 8.64 (s). MS (ESI): m/z 434 (M + Na+). 
  
Ethyl 5-phenylimidazo[1,5-a]quinoline-3-carboxylate (8a). AB123 
This compound was prepared from 2861 (0.20 g, 0.834 mmol), ethyl isocyanoacetate (0.28 mL, 
2.56 mmol), and potassium tert-butoxide (0.27 g, 2.41 mmol) according to the above general 
procedure and purified by flash chromatography with ethyl acetate as the eluent to obtain 8a as a 
white solid (0.24 g, yield 91%, mp 244-245 °C). 1H NMR (400 MHz, CDCl3): 1.43 (t, J = 7.0, 3H), 
4.45 (q, J = 7.0, 2H), 7.36-7.54 (m, 6H), 7.65 (t, J = 7.6, 1H), 7.77 (d, J = 8.1, 1H), 8.02 (s, 1H), 
8.09 (d, J = 8.2, 1H), 8.64 (s, 1H). 13C NMR (100 MHz, CDCl3): 14.6, 60.5, 115.1, 117.2, 123.9, 
124.6, 126.1, 127.8, 128.1, 128.3, 128.6, 129.6, 130.7, 132.4, 138.1, 138.4, 163.4. MS (ESI): m/z 
339 (M + Na+). 
 
tert-Butyl 5-phenylimidazo[1,5-a]quinoline-3-carboxylate (8b). AB189 
This compound was prepared from 2861 (1.0 g, 4.17 mmol), tert-butyl isocyanoacetate (1.8 mL, 
12.4 mmol), and potassium tert-butoxide (1.4 g, 12.5 mmol) according to the above general 
procedure and purified by flash chromatography with n-hexane-ethyl acetate (1:1) as the eluent to 
obtain 8b as a white solid (1.0 g, yield 70%, mp 231-233 °C). 1H NMR (400 MHz, CDCl3): 1.66 (s, 
9H), 7.37-7.55 (m, 6H), 7.67 (t, J = 7.5, 1H), 7.79 (d, J = 8.0, 1H), 8.04 (s, 1H), 8.11 (d, J = 8.1, 
1H), 8.68 (s, 1H). 13C NMR (100 MHz, CDCl3): 28.5, 81.1, 115.1, 117.5, 123.8, 125.9, 126.0, 127.5, 
128.1, 128.2, 128.6, 129.5, 130.8, 132.0, 138.0, 138.2, 162.9. MS (ESI): m/z 367 (M + Na+). 
 
tert-Butyl 4-methyl-5-phenylimidazo[1,5-a]quinoline-3-carboxylate (8e). AB203 
This compound was prepared from 2942 (1.0 g, 3.94 mmol), tert-butyl isocyanoacetate (1.7 mL, 
11.7 mmol), and potassium tert-butoxide (1.3 g, 11.6 mmol) according to the above general 
procedure and purified by flash chromatography with n-hexane-ethyl acetate (1:1) as the eluent to 
obtain 8e as a creamy solid (0.30 g, yield 21%, mp 204-205 °C). 1H NMR (400 MHz, CDCl3): 1.65 
(s, 9H), 2.43 (s, 3H), 7.18 (d, J = 8.1, 1H), 7.22-7.26 (m, 2H), 7.27-7.35 (m, 1H), 7.46-7.56 (m, 4H), 
8.03 (d, J = 8.3, 1H), 8.69 (s, 1H). MS (ESI): m/z 381 (M + Na+). 
  
Diethyl 5-phenylimidazo[1,5-a]quinoline-3,4-dicarboxylate (8g). AB128 
This compound was prepared from 3062 (0.36 g, 1.15 mmol), ethyl isocyanoacetate (0.38 mL, 3.48 
mmol), and potassium tert-butoxide (0.37 g, 3.30 mmol) according to the above general procedure 
and purified by flash chromatography with ethyl acetate as the eluent to obtain 8g as a white solid 
(0.26 g, yield 58%, mp 163-164 °C). 1H NMR (400 MHz, CDCl3): 0.97 (t, J = 7.1, 3H), 1.40 (t, J = 
7.1, 3H), 4.12 (q, J = 7.1, 2H), 4.39 (q, J = 7.1, 2H), 7.29-7.40 (m, 4H), 7.42-7.50 (m, 3H), 7.62-7.68 
(m, 1H), 8.08 (d, J = 8.4, 1H), 8.72 (s, 1H). 13C NMR (100 MHz, CDCl3): 13.6, 14.5, 60.7, 61.4, 
114.7, 123.3, 124.2, 125.6, 126.4, 127.7, 128.2, 128.5, 129.1, 130.0, 130.2, 130.4, 135.0, 136.3, 
162.7, 165.3. MS (ESI): m/z 411 (M + Na+). 
 
Ethyl 4-(2-ethoxy-2-oxoethyl)-5-phenylimidazo[1,5-a]quinoline-3-carboxylate (8h). AB129 
This compound was prepared from 3142 (0.20 g, 0.614 mmol), ethyl isocyanoacetate (0.24 mL, 
2.20 mmol), and potassium tert-butoxide (0.20 g, 1.78 mmol) according to the above general 
procedure and purified by flash chromatography with ethyl acetate as the eluent to obtain 8h as a 
white solid (0.14 g, yield 57%, mp 186-187 °C). 1H NMR (400 MHz, CDCl3): 1.18 (t, J = 7.1, 3H), 
1.43 (t, J = 7.1, 3H), 4.10 (q, J = 7.1, 2H), 4.15 (s, 2H), 4.40 (q, J = 7.1, 2H), 7.19 (d, J = 8.2, 1H), 
7.22-7.27 (m, 2H), 7.34 (t, J = 7.7, 1H), 7.44-7.51 (m, 3H), 7.61 (t, J = 7.8, 1H), 8.08 (d, J = 8.3, 
1H), 8.73 (s, 1H). MS (ESI): m/z 425 (M + Na+). 
 
5-Phenylimidazo[1,5-a]quinoline-3-carboxylic acid (32). AB190 
A mixture of 8b (1.0 g, 2.90 mmol) in formic acid (10 mL) was stirred at room temperature 
overnight and then concentrated under reduced pressure to obtain acid 32 as an off-white solid (0.75 
g, yield 90%, mp 264-265 °C). 1H NMR (200 MHz, DMSO-d6): 7.45-7.81 (m, 9H), 8.58 (d, J = 8.2, 
1H), 9.25 (s, 1H) 12.59 (br s, 1H). MS (ESI): m/z 289 (M + H+). 
 
4-Methyl-5-phenylimidazo[1,5-a]quinoline-3-carboxylic acid (33). AB204 
 A mixture of 8e (0.20 g, 0.558 mmol) in formic acid (10 mL) was stirred at room temperature 
overnight and then concentrated under reduced pressure to obtain acid 33 (0.15 g, yield 89%), which 
was used in the subsequent step without any further purification. 1H NMR (200 MHz, DMSO-d6): 
2.47 (s, 3H), 7.11-7.57 (m, 8H), 8.42 (d, J = 8.2, 1H), 8.99 (s, 1H) 12.59 (br s, 1H).  
(Non c’è campione) 
 
N,N-Dimethyl-5-phenylimidazo[1,5-a]quinoline-3-carboxamide (8c). AB192, VC885 
To a mixture of acid 32 (0.40 g, 1.39 mmol) in acetonitrile (17 mL) and water (34 mL) was added 
a 0.1M solution of sodium carbonate up to pH 7.5 and then a solution of 2,3,5,6-terafluorophenol 
(0.46 g, 2.77 mmol) in acetonitrile (1.0 mL) and EDC hydrochloride (0.53 g, 2.76 mmol). The 
reaction mixture was stirred at room temperature for 4 h and the precipitate was collected by 
filtration and purified by flash chromatography to obtain the corresponding 2,3,5,6-terafluorophenyl 
ester as an off-white solid (0.34 g, yield 56%, mp 243-245 °C), which was promptly used in the 
subsequent step without any further purification. 1H NMR (200 MHz, CDCl3): 6.91-7.08 (m, 1H), 
7.40-7.52 (m, 6H), 7.67-7.82 (m, 2H), 7.98 (s, 1H), 8.15 (d, J = 8.3, 1H), 8.80 (s, 1H). MS (ESI): 
m/z 459 (M + Na+). To a solution of the 2,3,5,6-tetrafluorophenyl ester (0.10 g, 0.229 mmol) in dry 
THF (15 mL), a 2M solution of dimethylamine in THF (0.35 mL, 0.70 mmol) was added. The 
reaction mixture was stirred at room temperature for 1 h and then concentrated under reduced 
pressure. Purification of the residue by flash chromatography with ethyl acetate-n-hexane (7:3) as 
the eluent gave 8c as a white solid (52 mg, yield 72%, mp 235-236 °C). 1H NMR (400 MHz, 
CDCl3): 3.15 (br s, 3H), 3.57 (br s, 3H), 7.41-7.49 (m, 6H), 7.63 (t, J = 7.7, 1H), 7.77 (d, J = 8.2, 
1H), 8.04-8.11 (m, 2H), 8.60 (s, 1H). MS (ESI): m/z 316 (M + H+). 
 
N-Benzyl-N-methyl-5-phenylimidazo[1,5-a]quinoline-3-carboxamide (8d). AB191, VC886 
This compound was prepared by using the same procedure described for 8c (with the exception 
that N-methylbenzylamine was used in place of dimethylamine) and purified by flash 
chromatography with n-hexane-ethyl acetate (1:1) as the eluent to obtain 8d as a white solid (yield 
 48%, mp 157-159 °C). Since the amide nitrogen of this compound bears two different substituents, 
its 1H NMR spectrum shows the presence of a (ca. 54:46) mixture of two different rotamers in 
equilibrium; for the sake of simplification the integral values have not been given. 1H NMR (400 
MHz, CDCl3): 3.03 (br s), 3.51 (br s), 4.81 (br s), 5.46 (br s), 7.28-7.54 (m), 7.63 (t, J = 7.3), 7.79 (d, 
J = 8.1), 8.06 (br s), 8.18 (br s), 8.58 (br s). MS (ESI): m/z 392 (M + H+). 
 
N-Benzyl-N,4-dimethyl-5-phenylimidazo[1,5-a]quinoline-3-carboxamide (8f). AB206 
This compound was prepared from acid 33 by using the same procedure described for 8c (with the 
exceptions that N-methylbenzylamine was used in place of dimethylamine) and purified by flash 
chromatography with ethyl acetate as the eluent to obtain 8f as a pale yellow glassy solid (yield 
67%). Since the amide nitrogen of this compound bears two different substituents, its 1H NMR 
spectrum shows the presence of a (ca. 54:46) mixture of two different rotamers in equilibrium; for 
the sake of simplification the integral values have not been given. 1H NMR (400 MHz, CDCl3): 2.24 
(s), 3.01 (s), 3.08 (s), 4.72 (s), 4.82 (s), 7.16-7.36 (m), 7.39 (d, J = 7.3), 7.42-7.57 (m), 7.89-8.08 
(m), 8.70 (s), 8.74 (s). MS (ESI): m/z 406 (M + H+). 
  
2-Chloro-3-hydroxymethyl-4-phenylquinoline (34).  AB131 
To a 1M solution of lithium aluminium hydride  (LAH, 20 mL, 20 mmol) cooled at 0-5 °C was 
added a solution of 3062 (3.0 g, 9.62 mmol) in THF (40 mL) and the resulting mixture was stirred at 
the same temperature for 15 min. The LAH excess was then decomposed with water and the reaction 
mixture was filtered and concentrated under reduced pressure. The residue was partitioned between 
dichloromethane and water and the organic layer was washed with brine, dried over sodium sulfate 
and concentrated under reduced pressure. Purification of the residue by flash chromatography with 
n-hexane-ethyl acetate (1:1) as the eluent afforded 34 (1.21 g, yield 47%), which was used in the 
subsequent step without any further purification. 1H NMR (200 MHz, CDCl3): 2.30 (t, J = 6.6, 1H), 
4.64 (d, J = 6.2, 2H), 7.29-7.75 (m, 8H), 8.02 (d, J = 8.3, 1H).  
 
 3-[(tert-Butyldimethylsilyloxy)methyl]-2-chloro-4-phenylquinoline (35).  AB132 
To a solution of 34  (1.2 g, 4.45 mmol) in dichloromethane (40 mL) containing imidazole (0.385 
g, 5.66 mmol) and cooled at 0-5 °C was added tert-butyldimethylsilyl chloride  (0.77 g, 5.1 mmol). 
The resulting mixture was stirred at the same temperature for 15 min and then at room temperature 
for 2.5 h. The reaction mixture was partitioned between dichloromethane and water and the organic 
layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure to 
afford 35 (1.4 g, yield 82%), which was used in the subsequent step without any further purification. 
1H NMR (200 MHz, CDCl3): 0.00 (s, 6H), 0.85 (s, 9H), 4.59 (s, 2H), 7.32-7.72 (m, 8H), 8.02 (d, J = 
8.4, 1H). MS (ESI): m/z 384, 386 (M + H+). 
 
Ethyl 4-[(tert-butyldimethylsilyloxy)methyl]-5-phenylimidazo[1,5-a]quinoline-3-carboxylate 
(36).  AB133 
This compound was prepared from 35 (1.38 g, 3.59 mmol), ethyl isocyanoacetate (1.3 mL, 11.9 
mmol), and potassium tert-butoxide (1.2 g, 10.7 mmol) according to the above general procedure to 
obtain pure 36 as a brown solid (1.35 g, yield 82%), which was used in the subsequent step without 
any further purification. 1H NMR (200 MHz, CDCl3): - 0.17 (s, 6H), 0.71 (s, 9H), 1.45 (t, J = 7.0, 
3H), 4.43 (q, J = 7.0, 2H), 5.00 (s, 2H), 7.23-7.63 (m, 8H), 8.06 (d, J = 8.2, 1H), 8.70 (s, 1H). MS 
(ESI): m/z 461 (M + H+). 
 
Ethyl 4-hydroxymethyl-5-phenylimidazo[1,5-a]quinoline-3-carboxylate (8i).  AB134 
To a solution of 36 (1.0 g, 2.17 mmol) in THF (40 mL) cooled at 0-5 °C was added a solution (1M 
in THF) of Bu4NF (4.3 mL, 4.3 mmol). The reaction mixture was stirred at the same temperature for 
30 min and overnight at room temperature, then diluted with water, and extracted with diethyl ether. 
The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced 
pressure. Purification of the residue by flash chromatography with ethyl acetate as the eluent gave 8i 
as a white solid (0.20 g, yield 27%, mp 192-193 °C). 1H NMR (400 MHz, CDCl3): 1.49 (t, J = 7.1, 
3H), 4.51 (q, J = 7.1, 2H), 4.64 (s, 2H), 5.13 (br s, 1H), 7.32 (d, J = 8.1, 1H), 7.35-7.41 (m, 3H), 
 7.45-7.56 (m, 3H), 7.64 (t, J = 7.7, 1H), 8.09 (d, J = 8.3, 1H), 8.78 (s, 1H). MS (ESI): m/z 369 (M + 
Na+). 
 
Ethyl 10,11-dihydro-9H-cyclopenta[c]imidazo[1,5-a]quinoline-1-carboxylate (9). AB124 
This compound was prepared from 3743 (0.16 g, 0.786 mmol), ethyl isocyanoacetate (0.26 mL, 
2.38 mmol), and potassium tert-butoxide (0.25 g, 2.23 mmol) according to the above general 
procedure and purified by flash chromatography with ethyl acetate as the eluent to obtain 9 as an off-
white solid (0.15 g, yield 68%, mp 200-201 °C).  1H NMR (400 MHz, CDCl3): 1.46 (t, J = 7.1, 3H), 
2.20-2.33 (m, 2H), 3.14 (t, J = 7.6, 2H), 3.59 (t, J = 7.4, 2H), 4.44 (q, J = 7.1, 2H), 7.50 (t, J = 7.5, 
1H), 7.59 (t, J = 7.7, 1H), 7.70 (d, J = 7.8, 1H), 8.02 (d, J = 8.3, 1H), 8.61 (s, 1H). MS (ESI): m/z 
281 (M + H+). 
 
General procedure for the synthesis of target imidazo[1,5-a]quinoxaline derivatives 10a-d. 
A solution of the suitable 4-acetyl-3,4-dihydroquinoxalin-2(1H)-one derivative (38 or 39) in dry 
THF was cooled at 0 °C for 10 min under argon and then treated with potassium tert-butoxide. The 
resulting mixture was allowed to warm at room temperature and stirred for 45 min under argon 
atmosphere. Then, it was cooled to -55 °C and diethyl chlorophosphate was added and the resulting 
mixture was stirred at -55 °C for 15 min and finally at room temperature for 45 min. The reaction 
mixture was cooled again at -55 °C and then treated with the suitable isocyanoacetate and potassium 
tert-butoxide. The resulting mixture was allowed to stir at -55 °C for 2 h and finally at room 
temperature for 30 min. Then, glacial acetic acid was added and the reaction mixture was 
concentrated under reduced pressure. The residue was dissolved in CHCl3 and washed with water 
and with brine. The organic layer was dried over sodium sulfate and concentrated under reduced 
pressure. Purification of the residue by flash chromatography with the appropriate eluent gave the 
expected target derivative (10a-d). 
 
Ethyl 5-acetyl-4,5-dihydroimidazo[1,5-a]quinoxaline-3-carboxylate (10a). AB84 
 This compound was prepared from 3831 (2.0 g, 10.5 mmol), potassium tert-butoxide (1.3 g, 11.6 
mmol), diethyl chlorophosphate (1.68 mL, 11.6 mmol), ethyl isocyanoacetate (1.8 mL, 16.5 mmol), 
and potassium tert-butoxide (1.3 g, 11.6 mmol) according to the above general procedure and 
purified by flash chromatography with ethyl acetate as the eluent to obtain 10a as an off-white 
crystalline solid (1.22 g, yield 41%). An analytical sample was obtained by recrystallization from 
ethyl acetate (colorless prisms, mp 173-174 °C).  1H NMR (400 MHz, CDCl3): 1.39 (t, J = 7.1, 3H), 
2.25 (s, 3H), 4.37 (q, J = 7.1, 2H), 5.24 (s, 2H), 7.30-7.59 (m, 4H), 8.02 (s, 1H). MS (ESI): m/z 308 
(M + Na+). 
tert-Butyl 5-acetyl-4,5-dihydroimidazo[1,5-a]quinoxaline-3-carboxylate (10b). QNX13h 
This compound was prepared from 3831 (1.0 g, 5.25 mmol), potassium tert-butoxide (0.65 g, 5.79 
mmol), diethyl chlorophosphate (0.84 mL, 5.81 mmol), tert-butyl isocyanoacetate (0.92 mL, 6.32 
mmol), and potassium tert-butoxide (0.65 g, 5.78 mmol) according to the above general procedure 
and purified by flash chromatography with ethyl acetate as the eluent to obtain 10b as a white solid 
(0.69 g, yield 42%). An analytical sample was obtained by recrystallization from ethyl acetate 
(colorless crystals, mp 184-185 °C, lit.23 150-152 °C). 1H NMR (400 MHz, CDCl3): 1.63 (s, 9H), 
2.28 (br s, 3H), 5.26 (br s, 2H), 7.29-7.59 (m, 4H), 8.01 (s, 1H). MS (ESI): m/z 336 (M + Na+). 
 
Ethyl 5-acetyl-7-fluoro-4,5-dihydroimidazo[1,5-a]quinoxaline-3-carboxylate (10c). AB85 
This compound was prepared from 39 (non noto) (150 mg, 0.72 mmol), potassium tert-butoxide 
(87 mg, 0.78 mmol), diethyl chlorophosphate (0.11 mL, 0.76 mmol), ethyl isocyanoacetate (0.12 
mL, 1.1 mmol), and potassium tert-butoxide (87 mg, 0.78 mmol) according to the above general 
procedure and purified by flash chromatography with ethyl acetate as the eluent to obtain 10c as a 
light-brown solid (70 mg, yield 32%). An analytical sample was obtained by recrystallization from 
cyclohexane-ethyl acetate (colorless crystals, mp 149-150 °C). 1H NMR (400 MHz, CDCl3): 1.42 (t, 
J = 7.1, 3H), 2.33 (s, 3H), 4.41 (q, J = 7.1, 2H), 5.25 (s, 2H), 7.02-7.12 (m, 1H), 7.41 (br s, 1H), 
7.49-7.59 (m, 1H), 7.99 (s, 1H). MS (ESI): m/z 326 (M + Na+). 
 
 tert-Butyl 5-acetyl-7-fluoro-4,5-dihydroimidazo[1,5-a]quinoxaline-3-carboxylate (10d). AB86 
This compound was prepared from 39 (non noto) (60 mg, 0.29 mmol), potassium tert-butoxide (37 
mg, 0.33 mmol), diethyl chlorophosphate (0.048 mL, 0.33 mmol), tert-butyl isocyanoacetate (0.067 
mL, 0.46 mmol), and potassium tert-butoxide (37 mg, 0.33 mmol) according to the above general 
procedure and purified by flash chromatography with ethyl acetate as the eluent to obtain 10d as a 
light-brown solid (30 mg, yield 31%). An analytical sample was obtained by recrystallization from 
ethyl acetate (colorless crystals, mp 208-209 °C). 1H NMR (400 MHz, CDCl3): 1.62 (s, 9H), 2.34 (s, 
3H), 5.23 (s, 2H), 7.03-7.11 (m, 1H), 7.39 (br s, 1H), 7.46-7.55 (m, 1H), 7.96 (s, 1H). MS (ESI): m/z 
354 (M + Na+). 
  
X-Ray crystallography. Single crystals of compounds 7p,s,t and 10a-c were submitted to X-ray 
data collection on an Oxford-Diffraction Xcalibur Sapphire 3 diffractometer with a graphite 
monochromated Mo-Kα radiation (λ = 0.71073 Å) at 293 K. The structures were solved by direct 
methods implemented in SHELXS-97 program.63 The refinements were carried out by full-matrix 
anisotropic least-squares on F2 for all reflections for non-H atoms by means of the SHELXL-97 
program.64 Crystallographic data (excluding structure factors) for the structure in this paper have 
been deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. 
CCDC 1437490 (7p, AB172), 1437488 (7s, AB160), 1437489 (7t, AB161) and 1437487 (10a, 
AB84), 1437486 (10b, QNX13h), 1446645 (10c, AB85). Copies of the data can be obtained, free of 
charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; (fax: + 44 (0) 1223 336 
033; or e-mail: deposit@ccdc.cam.ac.uk). 
 
Radioligand Binding Studies in native bovine and human cerebral receptors. [3H]flumazenil 
(specific activity 70.8 Ci/mmol) was obtained from Perkin-Elmer Life Science (Milano, Italy). All 
other chemicals were at reagent grade and were obtained from commercial suppliers. 
Bovine cortex was obtained from the local slaughterhouse. Human cortex samples were taken post-
mortem at the Department of Pathological Anatomy, University of Pisa, during autopsy sessions. 
 The subjects had died from causes not primarily involving the brain and had not suffered from any 
psychiatric or neurological disorders. The time between death and tissue dissection/freezing ranged 
from 18 to 36 h. The samples were immediately packed in dry ice and stored in a -80° freezer. The 
study was approved by the Ethics Committee of the University of Pisa, Italy. 
Bovine and human cerebral cortex membranes were prepared in accordance with Martini et al.65 
Briefly, cerebral cortex was homogenized in 10 volumes of ice cold 0.32 M sucrose containing 
protease inhibitors. The homogenate was centrifuged at 1000 g for 10 min at 4 °C, the resulting 
pellet was discarded and the supernatant was re-centrifuged at 48000 g for 15 min at 4 °C. Then the 
pellet was osmotically shocked by suspension in 10 volumes of 50 mM Tris-citrate buffer at pH 7.4 
containing protease inhibitors and re-centrifuged at 48000 g for 15 min at 4 °C. The resulting 
membranes were frozen and washed by means of a procedure previously described for removing 
endogenous GABA from cerebral cortex.66 Finally, the pellet was suspended in 10 volumes of 50 
mM Tris-citrate buffer pH 7.4 and used in the binding assay. Protein concentration was assayed by 
the method of Lowry et al.,67 by means of bovine serum albumin as the standard. 
[3H]flumazenil binding studies were performed as previously reported.68 The [3H]flumazenil binding 
was performed in triplicate by incubating aliquots of the membrane fractions (0.2-0.3 mg of protein) 
at 0 °C for 90 min in 0.5 mL of 50 mM Tris-citrate buffer, pH 7.4, with approximately 0.2 nM 
[3H]flumazenil. Non-specific binding was defined in the presence of 10 M diazepam. After 
incubation, the samples were diluted at 0 °C with 5 mL of the assay buffer and immediately 
harvested onto GF/B filters (Brandel) by means of a harvester and washed with ice-cold assay 
buffer. The filters were washed twice with 5 mL of the buffer, dried and 4 mL of Ready Protein 
Beckman scintillation cocktail were added; radioactivity was counted in a Packard LS 1600 liquid-
phase scintillation  counter. 
Compounds were routinely dissolved into DMSO and added to the assay mixture to amount to a 
final volume of 0.5 mL. Blank experiments were carried out to determine the effect of the solvent 
(2%) on binding. At least six different concentrations spanning 3 orders of magnitude, adjusted 
approximately for the IC50 of each compound, were used. IC50 values, computer-generated by a 
 nonlinear formula on a computer program (GraphPad, San Diego, CA), were converted to Ki values, 
the Kd values of radioligand in these different tissues calculated by the Cheng and Prusoff equation 
being known.69 The Kd of [
3H]flumazenil binding to cortex membrane from bovine and human was 
0.85 nM and 0.91 nM, respectively. The GABA ratio was determined by calculating Ki without 
GABA/Ki with GABA 50 M for each compound.  
 
In vitro efficacy in 36Cl- uptake assay in rat cerebrocortical synaptoneurosomes. 36Cl- (specific 
activity 9.69 Ci/g) was obtained from Perkin-Elmer Life Science (Milan, Italy). All other chemicals 
were reagent grade and were obtained from commercial suppliers. 
36Cl- uptake was measured in rat cerebrocortical synaptoneurosomes as described by Schwartz et 
al.,48 with minor modifications. Briefly, cerebral cortex was dissected from Sprague-Dawley male 
rats suspended 1:10 with ice-cold solution containing 145 mM NaCl, 5 mM KCl, 5 mM MgCl2, 1 
mM CaCl2, 10 mM HEPES, pH 7 (T1 buffer), and 10 mM D-glucose; they were homogenized with 
a glass-glass homogenizer (five strokes) and filtered through three layers of nylon mesh (160 m) 
and a 10 m Millipore filter. The filtrates were centrifuged at 1000 g for 15 min. After discarding 
the supernatant, the pellet was gently re-suspended in T1 buffer and washed once more by 
centrifugation (1000 g for 15 min). The final pellet containing the synaptoneurosomes was 
suspended 1:2 in T1 buffer and kept on ice until ready for assay (no longer than 30 min). 
Aliquots of synaptoneurosome suspensions (1.5-2 mg of protein) were pre-incubated at 30 °C for 10 
min prior to the addition of 0.2 Ci of 36Cl-. Drugs were added simultaneously with the 36Cl- (0.35 
mL total assay volume). 36Cl- uptake was stopped 10 sec later by the addition of 5 mL of ice-cold 
HEPES, followed by vacuum filtration through glass fiber filters (Whatman GF/B) that had been 
soaked with 0.05% polyethylenimine to reduce non-specific binding of 36Cl-. The filters were 
washed three more times with 5 mL of ice-cold buffer and placed into scintillation vials containing 4 
mL of Ready Protein Beckman scintillation cocktail and radioactivity was counted in a Packard LS 
1600 liquid-phase scintillation  counter. Data are expressed as per cent stimulation of 36Cl- uptake 
above basal level. 
  
In vitro efficacy in excytotoxic-mediate injury. Compounds. Trizma® base, ascorbic acid, 
sodium pyruvate, sodium EGTA, β-nicotinamide adenine dinucleotide (NAD+), β-nicotinamide 
adenine dinucleotide reduced form (NADH) and all artificial cerebrospinal fluid (ACSF) 
components were purchased from Sigma-Aldrich Co. (St Louis, MO, U.S.A.). Drugs molecules were 
solubilized in DMSO and diluted at the final desired concentration with ACSF immediately before 
the experiment. Final DMSO concentration in the ACSF used for the experiments was always lower 
than 0.1%, which had no effect per se on the biochemical parameters investigated.54,59 All other 
materials were from standard local commercial sources and of the highest grade available.  
Animals. All experiments were performed in strict compliance with national and international 
guidelines for the care and use of laboratory animals and the protocols were approved by the Animal 
Care and Ethics Committee of the University of Siena, Italy. Sprague-Dawley male rats (300-350 g; 
Charles River Italia, Calco, Italy) were kept in large cages under a 12:12 h day-night cycle at 20 °C 
ambient temperature. Drinking water and conventional laboratory rat food were available ad libitum. 
Before sacrifice, animals were anaesthetized by intraperitoneal injection of a mixture of Ketavet (30 
mg/kg ketamine; Gellini, Aprilia, Italy) and xylazine (8 mg/kg Xilor; Bayer AG, Wuppertal, 
Germany).  
Preparation of slices. After sacrifice of the animal (by decapitation) the whole brain was rapidly 
removed, chilled to 4 °C by immersion into cold ACSF (composition in mM: 120 NaCl, 2.5 KCl, 1.3 
MgCl2, 1.0 NaH2PO4, 1.5 CaCl2, 26 NaHCO3, 11 glucose, saturated with 95% O2 -5% CO2, with a 
final pH of 7.4, osmolality 285-290 mOsmol). The cortex was dissected and cut into 400 µm-
thickness slices by using a manual chopper (Stoelting Co., Wood Dale, IL, USA). Afterward, slices 
were maintained in oxygenated ACSF enriched with 400 µM ascorbic acid for 1 h at room 
temperature to allow maximal recovery from slicing trauma. 59 
In vitro ischemia-like conditions. Cortical slices from a single brain were placed in covered 
incubation flasks containing ACSF (2 mL) continuously bubbled with a 95% O2 - 5% CO2 gas 
mixture and incubated at 37 °C for an additional period of 30 min. Afterwards, OGD was carried out 
by incubating slices for 30 min into ACSF in which glucose was replaced by an equimolar amount 
 of sucrose, and continuously bubbled with a 95% N2 - 5% CO2 gas mixture. After the OGD phase, 
the ischemic-like solution was replaced with fresh, oxygenated ACSF for an additional 90 min 
period (reoxygenation phase). The protective effect of the tested compounds was investigated by 
adding them to ACSF during the entire reoxygenation phase. 
Assessment of tissue injury. Cell damage was assessed by measuring the amount of LDH released 
into the ACSF during the entire reperfusion period.54,59 LDH activity was determined 
spectrophotometrically via the rate of decrease in absorbance at 340 nm of NADH during its 
oxidation to NAD+ and the concomitant reduction of pyruvate to lactate.  
Data Analysis. Each experimental block was performed by using brain slices derived from at least 
4 rats. Data are reported as mean ± SEM and statistical analysis was performed by using one-way 
ANOVA followed by Dunnet post-test (GraphPad Software, San Diego, CA, USA). In all 
comparisons, the level of statistical significance (P) was set at 0.05.  
 
In vivo efficacy. The experiments were carried out in accordance with the Animal Protection Law 
of the Republic of Italy, DL No. 116/1992, based on the European Communities Council Directive 
of November 24, 1986 (86/609/EEC). All efforts were made to minimize animal suffering and to 
reduce the number of animals involved. Male CD-1 albino mice (22–24 g) and male Swiss Webster 
(20–26 g) (Morini, Italy) were used. Twelve mice were housed per cage and fed a standard 
laboratory diet, with tap water ad libitum for 12 h/12 h light/dark cycles (lights on at 7:00). The 
cages were brought into the experimental room the day before the experiment for acclimatization 
purposes. All experiments were performed between 10:00 and 15:00. 
Rota-rod test. The integrity of the animals’ motor coordination was assessed using a rota-rod 
apparatus (Ugo Basile, Varese, Italy) at a rotating speed of 16 rpm. The treatment was performed 
before the test. The numbers of falls from the rod were counted for 30 s, 30 min after drug 
administration, and the test was performed according to the method described by Vaught et al.70 
Light-dark box test. The apparatus (50 cm long, 20 cm wide, and 20 cm high) consisted of two 
equal acrylic compartments, one dark and one light, illuminated by a 60 W bulb lamp and 
separated by a divider with a 10 x 3 cm opening at floor level. Each mouse was tested by placing 
 it in the centre of the lighted area, away from the dark one, and allowing it to explore the novel 
environment for 5 min. The number of transfers from one compartment to the other and the time 
spent in the illuminated side were measured. This test exploited the conflict between the animal's 
tendency to explore a new environment and its fear of bright light.71 
Passive-avoidance test. The test was performed according to the step-through method described by 
Jarvik et al.72 The apparatus consisted of a two-compartment acrylic box with a lighted compartment 
connected to a darkened one by a guillotine door. As soon as the mouse entered the dark 
compartment, it received a thermal shock punishment. The latency times for entering the dark 
compartment were measured in the training test and after 24 h in the retention test. The maximum 
entry latency allowed in the training and retention sessions was, respectively, 60 and 180 s. 
Hole-board test. The hole-board test consisted of a 40 cm2 plane with 16 flush-mounted cylindrical 
holes (3 cm diameter) distributed four by four in an equidistant, grid-like manner. Mice were placed 
on the center of the board one by one and allowed to move about freely for a period of 5 min each. 
Two electric eyes, crossing the plane from midpoint to midpoint of the opposite sides, thus dividing 
the plane into four equal quadrants, automatically signaled the movement of the animal (counts in 5 
min) on the surface of the plane (spontaneous motility). Miniature photoelectric cells in each of the 
16 holes recorded (counts in 5 min) the exploration of the holes (exploratory activity) by the mice. A 
total of 12–15 mice per group were tested.73 
Compound administration. Diazepam (Valium 10, Roche) was dissolved in isotonic (NaCl 0.9%) 
saline solution and injected subcutaneously. The new compounds were administered by the po route 
and was suspended in 1% carboxymethylcellulose sodium salt and sonicated immediately before 
use. Drug concentrations were prepared in such a way that the necessary dose could be administered 
in a 10 mL/kg volume of carboxymethylcellulose 1% by the per os or subcutaneous route. 
Statistical analysis. All experimental result are given as the mean  SEM. Each value represents the 
mean of 25 mice. An analysis of variance, ANOVA, followed by Fisher’s protected least significant 
difference procedure for post hoc comparison, were used to verify significance between two means 
 of behavioral results. The data were analyzed with the StatView software for Macintosh (1992).  P 
values of less than 0.05 were considered significant.  
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